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ABSTRACT 
 
 
Metastasis is the leading cause of cancer-related deaths. Although there are many 
factors that promote and facilitate invasive tumors—angiogenesis and lymphangiogenesis 
provide a means by which invasive tumor cells can spread to distant organs. Semaphorins 
(SEMAs) were originally discovered for their role in axon guidance during development, 
however, SEMAs are now known for their anti-metastatic potential. SEMA3F is a 95-
kDA protein that induces both anti-angiogenic and anti-lymphangiogenic effects by 
binding its receptor, Neuropilin 2 (NRP2). SEMA3F-induced signaling via 
NRP2/plexinA1 complexes inhibits RhoA and results in f-actin depolymerization. 
SEMA3F may also inhibit angiogenic and lymphangiogenic signaling by competitive 
inhibition of VEGF-C and VEGF-A binding to NRP2. In this study we have purified 
SEMA3F protein for use in several in vitro and in vivo studies. Endothelial cell spheroids 
were unable to produce sprouts during an in vitro spheroid sprouting assay when treated 
with SEMA3F. In addition, treatment with SEMA3F induced f-actin depolymerization 
! #"!
and cell collapse during in vitro endothelial cell collapse assays. A375SM human 
melanoma cells were injected in nude mice and treated with SEMA3F purified protein. 
The resultant tumors showed decreased intra- and peri-tumoral lymphatic and vascular 
densities. Tumors in SEMA3F treated mice were also found to be more necrotic than 
those of the control. In a second study, slow release osmotic pumps containing SEMA3F 
protein were implanted in Nrp2+/LacZ heterozygous mice prior to the injection of B16F10 
mouse melanoma cells. These mice exhibited decreased tumor volumes indicating 
SEMA3F may inhibit tumorigenesis. These results indicate the potential of SEMA3F as 
an anti-metastatic/anti-tumorigenic therapeutic.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! #""!
TABLE OF CONTENTS 
 
Title           i 
Reader’s Approval Page  ii 
Acknowledgements  iii 
Abstract                                        v 
Table of Contents         vii 
List of Tables          ix 
List of Figures          x 
List of Abbreviations  xii 
Introduction 1 
 a. Hallmarks of cancer 2 
 b. Metastasis and metastatic events 4 
 c. Angiogenesis 7 
 d. VEGF and VEGFR 14 
 e. Neuropilin family of receptors 17 
 f. The role of semaphoring and plexin 22 
 g. Plexins 25 
 h. Investigating the anti-metastatic effects of SEMA3F 27 
 i. Lymphangiogenesis: the next frontier 34  
Specific Aims 36 
Methods and Materials 37 
! #"""!
Results 57  
Discussion 73 
References  83 
Curriculum Vitae 99 
      
 
                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! "$!
LIST OF TABLES 
 
Table Title Page  
1 Cell Line Specific Culture Details 38 
2 Antibodies and Dilutions Used During Western Blot Analysis 43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! $!
LIST OF FIGURES 
Figure  Title Page  
1 Hallmarks and enabling characteristics of cancer 3 
2 The metastatic cascade 5 
3 Tumor and the tumor microenvironment 6 
4 Normal Angiogenesis 9 
5 Tumor Angiogenesis 10 
6 The Angiogenic Switch 13 
7 VEGF ligands and their receptors 16 
8 Structural representation of NRP receptors 20 
9 Structural representation of SEMA3 family of proteins with furin-
like protease cleavage sites 
24 
10 Effects of SEMA3F on tumor angiogenesis 28 
11 The SEMA3F induced Plxn/ABL2/RhoA pathway 30 
12 The SEMA3F induced FARP2/RND1/PlxnA1 pathway 32 
13 SEMA3F induced tumor inhibition via integrin signaling 33 
14 SEMA3F purification process, protein analysis, and in vitro 
bioassays 
51 
15 Structural analysis of purified SEMA3F 58 
16 NRP2 expression in PAENRP2R cell line 59 
17 Comparison of pre- and post-lyophilized SEMA3F protein via 
western blot analysis 
60 
! $"!
18 SEMA3F induces f-actin depolymerization causing PAENRP2R 
cells to collapse 
61 
19 SEMA3F inhibited sprouting in PAENRP2R spheroid assays  63 
20 SEMA3F transduced COS7 cells show slight intracellular 
SEMA3F expression 
64 
21 Western blot analysis determined adenoviral transduction to be 
unsuccessful in vivo 
65 
22 Daily injections of SEMA3F lead to tumor necrosis in nude mice 66 
23 Experiment M: Initial histological analysis of SEMA3F treated 
tumors indicates fewer intratumoral and peritumoral vessels 
67 
24 Experiment N: Histological analysis of SEMA3F treated tumors 
does not indicate a significant difference in MVD or total vessel 
area 
68 
25 Quantitative analysis from Experiments M and N indicates low 
dose SEMA3F treatment was effective 
69 
26 Resected tumors from Experiment N depict fewer and smaller 
lymphatic vessels in SEMA3F treated tumors 
71 
27 SEMA3F pumps implanted before initial injection of B16F10 in 
nude mice decreased tumor volume 
72 
 
 
 
! $""!
ABBREVIATIONS 
 
Ab  Antibody 
APS  Amonium Persulfate 
bFGF  Basic Fibroblast Growth Factor 
BCE  Bovine Capillary Endothelial cell line 
BSA  Bovine Serum Albumin 
COS7  African Green Monkey Kidney cell line  
CUB  Complement Binding 
Cys  Cysteine 
DAB  3,3-Diaminobenzidine 
ddH2O  Autoclaved Double Distilled Water 
DMEM Dulbecco’s Modified Eagle Medium 
EC  Endothelial Cell 
ECM  Extracellular Matrix 
EDTA  Ethylenediaminetetraacetic Acid 
ERK  Extracellular-signal-regulated Kinase 
FBS  Fetal Bovine Serum 
FGF  Fibroblast Growth Factor 
FN  Fibronectin 
FPLC  Fast Protein Liquid Chromatography 
GAP  GTPase-activating 
! $"""!
GPS  L-Glutamine/Penicillin/Streptomycin 
HBD  Heparin Binding Domain 
H&E  Hematoxylin and Eosin 
HEK 293 Human Embryonic Kidney 293 cell line 
HET  NRP2+/LacZ transgenic mice  
HIF-1! Hypoxic Inducible Factor-1! 
HIF-1" Hypoxic Inducible Factor-1" 
His  HistidineLL 
HRP  Horseradish Peroxidase 
Ig  Immunoglobulin 
IHC  Immunohistochemistry 
IL-1"  Interleukin-1" 
ILK  Integrin-linked Kinase 
IPT  Immunoglobulin-plexin-transcription 
kDa  kilodaltons 
LEC  Lymphatic Endothelial Cell  
MAM  Meprin/A5-protein/PTPmu 
MEM  Minimal Essential Media 
Mets  Metastases 
MMPs  Matrix Metalloproteinases 
MMP9  Matrix Metalloproteinase-9 
MVD  Micro Vessel Density 
! $"#!
NO  Nitric Oxide 
NRP  Neuropilin (Human) 
Nrp  Neuropilin (mouse) 
PAE  Porcine Aortic Endothelial Cell 
PFA  Paraformaldehyde 
PAENRP2 PAENRP2 Red Hi Cell Line 
PAENRP2R PAE cell line transfected with NRP2 and RFP 
PBS  Phosphate Buffered Saline 
PCS  Proteolytic Cleavage Site 
PlGF  Placental Growth Factor 
PDGF  Platelet Derived Growth Factor 
Plxn  Plexin 
PSI  Plexin-Semaphorin-Integrin Domain 
RFP  Red Fluorescent Protein 
RIPA  Radio Immuno Precipitation Assay 
RTK  Receptor Tyrosine Kinase 
SA-HRP Streptavidin-Horseradish Peroxidase Conjugate 
SEMA  Semaphorin (human) 
Sema  Semaphorin (mouse) 
sNRP  Soluble Neuropilin 
TBS  Tris Buffered Saline 
TEMED Tetramethylethylenediamine  
! $#!
TNB  Tris-NaCl Blocking Buffer 
TSP-1  Thrombospondin 1 
U87MG Human Glioblastoma cell line 
VEGF  Vascular Endothelial Growth Factor  
VEGFR Vascular Endothelial Growth Factor Receptor 
VN  Vitronectin 
 
! "!
INTRODUCTION 
 
As the second leading cause of death, cancer was responsible for over 570,000 
deaths in the United States in 2010 (Centers for Disease Control, 2013). Cancer, a term 
that encompasses over one hundred forms of malignant neoplasms, is prevalent in all 
socio-economic classes, races, and geographic regions of the world and is considered as 
one of the leading causes of disease, contributing to approximately 13% of deaths 
worldwide in 2008 (World Health Organization, 2012). Cancer is deeply rooted in 
medical history with descriptions of cancer dating back to Egypt around 3000 BC, while 
the designation of “carcinoma”, as coined by the Greek physician Hippocrates, arrived 
sometime between 460-370 BC (American Cancer Society, 2012). Although 
chemotherapy and radiotherapy remain the standard of care for many forms of inoperable 
cancer, advances in medicine and biotechnology are paving the way for targeted therapies 
such as Gleevec (imatinib mesylate), which interrupts specific molecular targets 
(Sawyers, 2004). The goal of targeted therapies is to focus on specific mechanisms or 
cells while decreasing the degree of non-specific cytotoxic effects. Complementing the 
advances in targeted approaches, increased rates of screening and advances in screening 
technology have decreased the number of incidences and mortalities associated with 
colorectal cancers (Schoen et al., 2012) and breast cancer in women over 40 (Taplin, 
2009). Although great strides have been made in attempting to understand how and why 
cancerous cells arise, many pieces of the puzzle are missing, leaving many questions 
unanswered. 
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Hallmarks of Cancer 
Although many forms of cancer exist, Hanahan and Weinberg have postulated 
that most, if not all, exhibit six traits that enable cancerous cells to override physiological 
defense mechanisms and become malignant. These six characteristics are: self-
sufficiency in growth signals, evasion of apoptosis, insensitivity to antigrowth signals, 
unlimited potential to replicate, ability to invade proximal tissue and metastasize, and the 
ability to induce angiogenesis (Hanahan & Weinberg, 2000). Self-sufficiency pertains to 
either the up-regulation of cytokines, growth factors, and/or growth signal receptors from 
the cell itself or with help from the tumor microenvironment (Allen & Louise Jones, 
2011). Evasion of apoptosis may occur through some fault in the p53, cytochrome C, or 
caspase (-8 and -9) pro-apoptotic signaling pathways or morphological factors such as the 
loss of e-cadherin and resulting resistance to anoikis induced apoptosis (Derksen et al., 
2006; Hanahan & Weinberg, 2000). The evasion of contact inhibition and insensitivity to 
tumor suppressor genes like retinoblastoma result in anti-growth insensitivity (Burkhart 
& Sage, 2008; Curto, Cole, Lallemand, Liu, & McClatchey, 2007). Overcoming 
senescence and gaining unlimited replicative potential is thought to result from up-
regulation of telomerase activity, ultimately allowing the cell to bypass both apoptosis 
and crisis (Blasco, 2002; Hanahan & Weinberg, 2011). The last two hallmarks are 
related. Angiogenesis, the recruitment of new vasculature to supply growing tumors with 
a sufficient blood supply, provides a means by which invasive cells can access distant 
organs and establish metastases (Mets).  
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Together these traits comprise the repertoire of capabilities that normal cells may 
acquire on their path towards tumorigenicity. Eleven years following their original 
manuscript, Hanahan and Weinberg included the “reprogramming of energy metabolism” 
and “evading immune destruction” to the arsenal of cancer hallmarks while stressing the 
importance of inflammation, genetic instability, and tumor microenvironment on the 
conversion of a normal cell to that of a tumorigenic one (Hanahan & Weinberg, 2011). 
By designating these traits as eight hallmarks of cancer is not to say that a particular 
cancerous cell exemplifies only one of these traits. In fact, many cells acquire varying 
combinations and degrees of these hallmarks without regard to any particular sequence in 
which they are inherited (Hanahan & Weinberg, 2000). The major role of some hallmarks 
is supportive; creating an environment that favors or enables the acquisition of further 
hallmarks. Such is the relationship between angiogenesis and the metastasis as explained 
below. 
 
Figure 1 | Hallmarks and enabling characteristics of cancer. Each of the major 
hallmarks and enabling factors of cancer are depicted along with potential therapeutic 
strategies that target them. From Hanahan 2011. 
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Growing evidence suggests that within a single tumor there exists a 
heterogeneous mixture of cancer cells (Hanahan & Weinberg, 2011; Naumov, Akslen, & 
Folkman, 2006). Genetically distinct subpopulations of tumor cells exhibiting different 
combinations of hallmarks and their own unique fingerprint of molecular targets thus 
complicating therapeutic approaches (Fidler, 2003; Talmadge & Fidler, 2010). Each 
hallmark comprises its respective field of cancer research and decades of acquired 
knowledge, ultimately framing a much larger picture of cancer physiology. However, 
invasion and metastasis proves to be the most clinically relevant, contributing to 90% of 
cancer related deaths (Hanahan & Weinberg, 2000; Sporn, 1997).  
 
Metastasis and Metastatic Events 
 Metastasis is the spread of cancer cells from a primary tumor to a secondary organ 
(Naumov et al., 2006).  The process of metastasis occurs by a series of events including 
tumor transformation, angiogenesis, cellular mobility and invasion of blood or lymphatic 
vessels, survival and transport of tumor cell aggregates through the circulation, arrest and 
embedding in distant organ capillary bed, extravasation of embedded tumor cells, and 
creation of a microenvironment that fosters tumor proliferation, angiogenesis, and the 
possibly future Mets (Figure 2) (Fidler, Kumar, Bielenberg, & Ellis, 1998; Talmadge & 
Fidler, 2010) This process of metastasis is quite arduous and the vast majority of 
circulating cancer cells fail to colonize secondary sites (Fidler, 2002) 
! &!
 
 
Figure 2 | The metastatic cascade. The process of metastasis is sequential, with each 
step as potentially rate limiting. Metastasis selects for only the most resilient and prolific 
sub populations of invasive tumor cells. From Fidler 2010. 
 
 
The transition from a wild type cell to an invasive cell is complex. Within primary 
tumor stroma are components that foster an invasive cell’s ability to break cell-cell 
connections, migrate through dense extracellular matrix (ECM), and intravasate nearby 
lymphatic and blood vessels (Egeblad, Nakasone, & Werb, 2010; Kessenbrock, Plaks, & 
Werb, 2010). These components—to name a few—consist of support cells like cancer-
associated fibroblasts, growth factors like basic fibroblast growth factor (bFGF) and 
vascular endothelial growth factor (VEGF), and metalloproteinases (MMPs) that degrade 
and restructure surrounding ECM (Figure 3) (Mueller & Fusenig, 2004). 
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Once cells have entered either a blood or lymphatic vessel, they must survive various 
physical and immunological stresses of the circulation until they arrest in a suitable 
capillary bed, extravasate, and establish a viable microenvironment (Fidler, 2002). These 
invasive cells do not arrive at the secondary site by coincidence.  
 
 
Figure 3 | Tumor and the tumor microenvironment. The complex interaction of a 
tumor and its microenvironment involves many players including ECs, macrophages, 
fibroblasts, and ECM. Proteases break down ECM components, releasing a mixture of 
tumorigenic and chemotactic factors. The tumor also secretes factors that work in both 
autocrine and paracrine manner some of which recruit fibroblasts and inflammatory cells 
that secrete further tumorigenic stimulants. From Mueller 2004 
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For more than a century, the “seed and soil” hypothesis has been used to describe 
the predisposition of some organs for the establishment of secondary tumor Mets. The 
capillary bed structure and local microenvironment of some organs are some of the many 
characteristics that make them better metastatic targets—better “soil”—for certain 
malignant cells—the “seeds”—than other organs (Nicolson, 1988; Paget, 1889; Tarin et 
al., 1984). Once embedded, the success of these micrometastases is dependent upon 
evasion of local immune cells and the recruitment of new vasculature via angiogenesis 
(Fidler, 2002). In fact, angiogenesis not only supplies the primary tumor with nutrients 
but also an access point by which invasive cells can travel throughout the body, colonize 
distant organs, and provide nutrients to would-be Mets.  
 
Angiogenesis 
Angiogenesis describes the process by which new capillaries sprout from existing 
blood vessels (Hanahan & Folkman, 1996). In addition to neoplastic diseases, 
pathological angiogenesis has been shown to play a role in infantile hemangiomas, 
psoriasis, arthritis, ocular neovascularization, and other non-neoplastic diseases 
(Folkman, 1995). Angiogenesis occurs in four distinct phases beginning with release of 
contact inhibition of endothelial cells (ECs)—either as a result of trauma or disruption of 
the basement membrane by MMPs—followed by migration of endothelial cells through 
perivascular stroma in the direction of pro-angiogenic factors (Auerbach & Auerbach, 
1994). The sprouting vessel, lead by a specialized tip cell, continues to proliferate toward 
the stimulus while adjusting to form an unobstructed and functional vessel lumen (Figure 
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4) (Chung, Lee, & Ferrara, 2010; Cockerill, Gamble, & Vadas, 1995; Gerhardt et al., 
2003).  
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Figure 4 | Normal Angiogenesis. The sequential steps of normal angiogenesis begin 
when angiogenic factors induce tip cell formation from a previously quiescent vessel (A). 
As the basement membrane breaks down and the tip cell migrates through the stroma 
towards the angiogenic stimulus, stalk elongation and pericyte recruitment help stabilize 
the emerging vessel (B). Following vessel fusion, further pericyte recruitment and 
basement membrane deposition and lumen formation help foster a fully perfused and 
functional neovessel. From Carmeliet 2011. 
! "+!
Hypoxia is one of the driving factors in normal physiological angiogenesis, initiating 
vessel growth in the absence of oxygen then vessel growth inhibition and stabilization 
once access to oxygen has been established (Chung et al., 2010). These new vessels are 
then stabilized by the recruitment of mural cells and the formation of a basement 
membrane to create competent vessels (Carmeliet & Jain, 2011). However, normal 
physiological angiogenesis differs from that of tumor angiogenesis. 
In tumor angiogenesis, the resulting vessels are unstable and highly permeable, 
lacking both adequate supporting pericytes and a stable basement membrane (Figure 5) 
(Nagy & Dvorak, 2012).  
 
 
Figure 5 | Tumor Angiogenesis. 1) Tumor begins secreting growth factors (GF), which 
stimulates tip cells (TC) to begin migrating through tissue stroma and extracellular matrix 
(ECM) from existing vasculature (steps 2-3). As the sprouting progresses, lumen 
formation occurs. Ultimately the tumor gains access to vasculature and may continue to 
grow. Invasive cells (IC) may breach the basement membrane surrounding these 
relatively leaky vessels and spread, possibly establishing metastases in distant organs. 
Adapted from van Horssen 2006.  
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Further studies have shown tumor vasculature to be structurally disorganized with 
aberrant branching and inconsistent lumenal diameters resulting in chaotic blood flow 
within these vessels (Chung & Chung, 2001; Hashizume et al., 2000). These 
characteristics that cause leaky tumor vessels and inefficient blood perfusion are the same 
characteristics that make these vessels especially prone to the intravasation of invasive 
cells as discussed earlier (Liotta, Steeg, & Stetler-Stevenson, 1991). Vascular anomalies 
in tumor angiogenesis arise from the methods in which a tumor initiates and carries out 
angiogenic signaling, which will be discussed in depth below.   
Although angiogenesis plays a key role in tumor metastasis, the initial purpose for 
recruiting vessels is nourishment. As tumors bypass dormancy and grow in size their 
need for nutrients and oxygen increases. Studies have shown cells residing further than 
200 !m from vessels—the diffusion limit of oxygen—suffer from hypoxic conditions 
(Filho, Leunig, Yuan, Intaglietta, & Jain, 1994). Due to this limitation non-angiogenic 
tumors rarely grow beyond 2-3 mm (Folkman, 1995). Indeed, many if not most tumors 
are harmless, either remaining dormant for years or never progressing to a disease state 
(Black & Welch, 1993; Folkman & Kalluri, 2004).  What then influences a tumor to 
become angiogenic and invasive?  
Regulation of the angiogenic cascade is a complex system consisting of many 
cellular players and quite a few pro- and anti-angiogenic factors. (Table 1) VEGF, bFGF, 
platelet derived growth factor (PDGF), placental growth factor (PlGF), matrix 
metalloproteinase-9 (MMP9), interleukin-1! (IL-1!), and hypoxic inducible factor-1"/! 
(HIF-1", HIF-1!) are a few pro-angiogenic factors that promote EC proliferation and 
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migration through various stages of angiogenesis (Bergers & Benjamin, 2003; Carmeliet, 
2000). Although the tumor, tumor stroma, epithelium, and inflammatory cells release the 
majority of these factors in response to hypoxic conditions in the tumor environment, 
growth factors are also stored in the ECM and can be released in response to matrix 
remodeling or degradation (Baeriswyl & Christofori, 2009; Marjon, Bobrovnikova-
Marjon, & Abcouwer, 2004; Taipale & Keski-Oja, 1997). The majority of these pro-
angiogenic molecules are ligands that activate various signaling cascades upon binding 
their respective tyrosine kinase receptor (Carmeliet, 2000). In addition to these pro-
angiogenic factors are many endogenous anti-angiogenic factors, the major ones being " 
and ! interferon, platelet factor-4, and thrombospondin-1 (TSP-1) (Hanahan & Folkman, 
1996). Dr. Judah Folkman, heralded as the father of modern angiogenesis, devised a 
model to simplify the complex interactions of angiogenic regulation. This angiogenic 
switch model describes a dynamic balance between pro- and anti-angiogenic factors. If 
the influence of angiogenic inducers outweighs that of the angiogenic inhibitors, the 
switch is turned on (Figure 6) (Hanahan & Folkman, 1996).  
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A 
 
 
 
 
 
 
B 
 
Figure 6 | The Angiogenic Switch. A) The angiogenic switch is a system balanced by 
pro- and anti-angiogenic factors. Whether or not angiogenesis occurs depends upon 
which group has the greater influence upon its environment. From Hanahan 1996. B) The 
angiogenic switch as it applies to tumor angiogenesis. Angiogenic factors may originate 
from the tumor, the or from bone marrow derived cells (BMDC) and immune cells 
recruited via tumor secreted chemotactic factors. Adapted from Baeriswyl 2009. 
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In the case of tumor angiogenesis, therapies attempt to sway the scale in favor of the 
inhibitors either by inactivating the ligands themselves, their receptors, or inhibiting their 
respective cell-signaling pathway further downstream. Of the angiogenic promoters, the 
most versatile in its ability to promote angiogenesis and thus most targeted factors are 
those of the VEGF family. 
 
VEGF and VEGFR 
The VEGF family consists of five growth signaling molecules, VEGFA, VEGFB, 
VEGFC, VEGFD, and PlGF. VEGFA is comprised of eight exons which after splicing 
gives rise to approximately 4 isoforms; VEGF121, VEGF165, VEGF189, and VEGF206 
(Tischer et al., 1991). Of these isoforms VEGF121 and VEGF165 appears to be the most 
prominent signaling isoforms due to their bioavailability and effectiveness (Ferrara, 
Gerber, & LeCouter, 2003). The VEGF family of polypeptides has a diverse set of 
functions including the induction of nitric oxide (NO) and prostacyclin, inhibition of 
smooth muscle cell proliferation, control of vessel permeability, suppression of 
thrombosis, anti-inflammatory effects, induction of lymphangiogenesis, and EC 
proliferation (Zachary, 2001). As mentioned above, the majority of VEGF ligands are 
secreted by parenchymal or tumor cells in response to HIF-1" (indicative of hypoxic 
conditions and poor blood perfusion) and other stimulants (Lee et al., 2007). The 
associated family of receptor tyrosine kinases (RTKs), vascular endothelial growth factor 
receptors 1-3 (VEGFR 1-3), have an extracellular ligand-binding/immunoglobulin (Ig)-
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like domain, a transmembrane domain, and an intracellular tyrosine kinase-signaling 
domain (Koch, Tugues, Li, Gualandi, & Claesson!Welsh, 2011).  
The VEGF ligands have specific affinities for particular VEGFRs (Figure 7). 
VEGFR1 is expressed in monocytes, macrophages, vascular smooth muscle cells, 
dendritic cells, and some human tumor cells with a relatively high level of expression in 
ECs (Koch et al., 2011; Peters, De Vries, & Williams, 1993). VEGFB and PlGF bind 
only VEGFR1 whereas VEGFA can bind either VEGFR1 or VEGFR2 but with a much 
higher affinity (more than 10x) for VEGFR1 (Shinkai et al., 1998). VEGFR1 signal 
transduction plays an important role in embryonic development of vasculature, wound 
healing, monocyte chemotaxis, and vessel formation and repair (Barleon et al., 1996; 
Peters et al., 1993). However, in ECs the ligand induced tyrosine kinase activity of 
VEGFR1 is low and may act only in the sequestering of VEGF ligand thus inhibiting 
VEGFR2 signal transduction (Meyer, Mohammadi, & Rahimi, 2006). Receptor signaling 
is attenuated via clatherin-mediated internalization of the receptor/ligand complex 
followed by proteolytic degradation (Kobayashi, Sawano, Nojima, Shibuya, & Maru, 
2004).  
VEGFR2 expression can be found in neural and retinal cells but is primarily 
expressed in ECs, influencing EC survival (via the Akt pathway), migration (via the 
HSP27/Rho/Paxillin pathways), proliferation (via the Ras/Raf pathway), and vessel 
permeability and it is the major inducer of angiogenic related processes (Jin, Mao, & 
Greenberg, 2000; Matsumoto & Mugishima, 2006; Yang & Cepko, 1996). Due to the 
numerous pro-angiogenic effects of the VEGFA/VEGFR2 pathway, therapies that target 
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this pathway have given rise to some of the most widely used cancer drugs (Peterson & 
Doherty, 2010). VEGFR2 may bind VEGFA and proteolytically processed VEGFC and 
VEGFD, both of which also bind VEGFR3 (Koch et al., 2011; McColl et al., 2003). Even 
though VEGFC and VEGFD bind both VEGFR2 and VEGFR3, proteolytically cleaved 
VEGFC has a higher affinity for VEGFR3 than VEGFR2 whereas VEGFD has a similar 
affinity for both VEGFR2 and VEGFR3 (Mäkinen et al., 2001). Like VEGFR1, VEGFR2 
may also be internalized but not necessarily degraded following endocytosis. Following 
internalization VEGFR2 may be recycled and reverted back to the plasma membrane 
while only endosomal VEGFR2 complexes can activate ERK and Akt signaling 
pathways (Lampugnani, Orsenigo, Gagliani, Tacchetti, & Dejana, 2006).  
 
 
Figure 7 | VEGF ligands and their receptors. VEGFRs may exist as either homo- or 
heterodimers. Each receptor has a specific set of interacting ligands. VEGFR1 may bind 
VEGFA, VEGFB, or PlGF. VEGFR2 binds VEGFA but may also bind processed 
VEGFC and VEGFD but with much lower affinity. VEGFR3 binds only VEGFC and 
VEGFD. Soluble VEGFRs lack signaling domains but may still bind and sequester 
available VEGF, effectively decreasing VEGFR signaling. From Koch, 2011. 
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VEGFR3 is mainly expressed by lymphatic ECs but is also expressed in tumor 
vasculature, angiogenic tip cells, osteoblasts, macrophages and neuronal progenitors 
(Koch et al., 2011; Partanen et al., 2000). VEGFR3 is primarily responsible for regulating 
lymphangiogenesis—a similar process to that of angiogenesis concerning lymphatic 
vasculature—and lymphatic EC survival through the JNK, PI3K, and ERK 1/2 pathways 
(Mäkinen et al., 2001). It is important to mention that factors intiating lymphangiogenesis 
are not dependant upon hypoxia unlike some key factors involved in the process of 
angiogenesis (Foskett, Ezekiel, Trzeciakowski, Zawieja, & Muthuchamy, 2011) 
In order for the VEGF polypeptides to bind and signal through their respective 
VEGFR, they must first form a covalently linked ligand dimer via two disulfide bridges 
at Cys-51 and Cys-60 (Muller et al., 1997; Stuttfeld & Ballmer-Hofer, 2009). Each 
VEGF monomer contains a cysteine knot motif which, along with dimerization, increases 
the ligand’s affinity for its RTK (Muller et al., 1997).  Once bound to the extracellular N-
terminal, these ligand dimers influence the homo- and heterodimerization of their target 
RTK, resulting in VEGFR autophosphorylation of tyrosine residues, and ultimately signal 
transduction (Hubbard & Miller, 2007).  
 
Neuropilin Family of Receptors 
A second family of receptors, neuropilins (NRPs), function as co-receptors to the 
VEGF and SEMA3 families. Originally NRPs were indicated in neuronal growth and 
guidance during embryonic development via a SEMA3 induced mechanism (Kolodkin et 
al., 1997; Takagi et al., 1991). In 1998, the Klagsbrun lab discovered that NRP functions 
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as a VEGF receptor and as the relationship between NRP, VEGF, and VEGFR became 
clearer, the field began to explore the role of NRP as a vital regulator of angiogenesis 
(Soker, Takashima, Miao, Neufeld, & Klagsbrun, 1998).  
The NRP family consists of two similarly structured receptors, NRP1 and NRP2, 
of approximately 130-140 kDa with an amino-acid homology of 44% (Figure 8) (Giger et 
al., 1998, p. 2). The molecular structure of NRPs is highly conserved among vertebrates 
and consists of a large extracellular domain, a transmembrane domain, and a short 
intracellular domain without known signaling capabilities. The extracellular domain is 
divided into several sub domains; two complement binding (CUB) domains designated as 
a1 and a2, two domains that share homology with coagulation factor V/VII designated as 
b1 and b2, and a meprin A5 mu (MAM) domain designated as c (Chen, Chédotal, He, 
Goodman, & Tessier-Lavigne, 1997). The MAM domain along with the transmembrane 
domain have been shown to play an important role in receptor dimerization while the 
transmembrane domain has an additional role in SEMA3A signal transduction (Giger et 
al., 1998; Roth et al., 2008). Receptor dimerization is an essential aspect of SEMA 
induced NRP signaling (Geretti, Shimizu, & Klagsbrun, 2008; Roth et al., 2008). In 
addition, the b1/b2 domain contains a heparin binding domain (HBD) that is essential for 
both ligand and receptor binding (Mamluk et al., 2002). Although two isoforms of the 
NRP1 receptor are known, several isoforms of the NRP2 receptor (NRP2a17, NRP2a22, 
NRP2b0, and NRP2b5) have been discovered, the majority of genetic variance residing in 
the transmembrane and intracellular domains (Rossignol, Gagnon, & Klagsbrun, 2000). 
The last three amino acids of the intracellular domain are conserved in both NRP1 and 
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NRP2A and has been shown to maintain some functional significance, illustrating the 
intracellular domain of NRPs, although small, does not lack functionality (Cai & Reed, 
1999). These three C-terminal amino acids (SEA) bind cytosolic proteins containing PDZ 
domains, namely Neuropilin Interacting Protein and is responsible for NRP1 mediated 
EC migration (Geretti et al., 2008). Lastly, soluble NRPs (sNRPs), truncated NRP 
receptors consisting of only a and b domains and thus able to bind both VEGF and 
SEMA3 proteins, have been discovered (Gagnon et al., 2000). These sNRPS are thought 
to play a role in tumor apoptosis via sequestering free VEGF, thus inhibiting VEGFR 
signaling and leading to VEGF withdrawal (Rossignol et al., 2000).  
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Figure 8 | Structural representation of NRP receptors. For simplification, receptors 
are depicted as monomers instead of active dimmer complexes. The CUB domain 
(a1/a2), coagulation factor-like domains (b1/b2), and the MAM (c) domains compose the 
extracellular aspect of the receptor. The transmembrane domain is also represented in 
both NRP1 and NRP2 receptors. Although relatively short, the cytoplasmic domain may 
possess functional significance. Also included is the structure for soluble NRP (sNRP). 
Adapted from Wild, 2012. 
 
 
VEGF binds NRP’s b1b2 domain (as does SEMA3 which will be described in 
greater detail below). The aforementioned cystine knot motif within VEGF ligands 
provides the main interaction site for binding VEGFRs whereas exon 7 of VEGF is 
necessary for binding NRPs (Soker, Fidder, Neufeld, & Klagsbrun, 1996; Wiesmann et 
al., 1997). Each NRP binds specific subset of VEGF ligands and VEGFRs. Although 
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both NRP1 and NRP2 bind VEGFA, they bind other members of the VEGF family as 
well as other growth factors with different affinities. NRPs are able to enhance both 
angiogenesis and lymphangiogenesis by forming complexes with VEGFRs. It is 
understood that NRP1 forms complexes with VEGFR1 and VEGFR2 whereas NRP2 
complexes mostly with VEGFR2 and VEGFR3 (Favier et al., 2006; Soker et al., 1998). 
Through formation of these complexes with VEGFRs, NRPs are able to enhance both 
pro-angiogenic and pro-lymphangiogenic signaling in ECs and lymphatic endothelial 
cells (LECs).  
Interaction of NRP2 with VEGFR2 and VEGFR3 lowers each receptor’s 
activation threshold, increasing VEGFR2’s sensitivity to VEGFA and VEGFC and 
VEGFR3’s sensitivity to VEGFC (Favier et al., 2006; Soker, Takashima, Miao, Neufeld, 
& Klagsbrun, 1998). Thus NRP2 is necessary for optimal VEGFR2 and VEGFR3 
autophosphorylation, playing an important role in EC and LEC survival, mitogenicity, 
and migration. Differential expression of NRPs will ultimately determine which cells and 
tissues are influenced by NRP1/2-dependant signaling. With regards to cardiovascular 
and lymphatic expression of these receptors, NRP1 is mainly found in arteries whereas 
veins and lymphatic tissue mainly express NRP2 (Bielenberg, Pettaway, Takashima, & 
Klagsbrun, 2006; Herzog, Kalcheim, Kahane, Reshef, & Neufeld, 2001). In addition, 
both NRP1 and NRP2 are not only expressed but also up-regulated in many types of 
tumors, indicating its potential as a therapeutic target (Ellis, 2006). 
Although both NRP1 and NRP2 maintain important functions during 
development, NRP1 knock-out mice exhibit fatal cardiovascular and neuronal defects 
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whereas NRP2 knock-outs are viable but develop aberrant lymphatic vasculature 
(Kawasaki et al., 1999; Yuan et al., 2002). These observations illustrate the necessity of 
NRP1 during embryonic development and the role of NRP2 in lymphatic development. It 
is now clear that NRP can enhance both angiogenesis and lymphangiogenesis via 
VEGFR-induced signal pathways. However, as mentioned briefly above, NRPs also 
interact with another family of molecules, class 3 semaphorins.  
 
The Role of Semaphorin and Plexin 
NRP was originally known for its chemorepellent effect on axonal guidance 
during embryonic development. In 1993, Luo et al. discovered the signaling protein that 
induced growth cone collapse during development of the chick brain, naming it 
“collapsin” (Luo, Raible, & Raper, 1993). Throughout the 1990s the search for similar 
proteins has led to the discovery of a family of molecules, semaphorins (SEMAs) that 
regulate cell adhesion, immune response, cell motility, angiogenesis, lymphangiogenesis, 
and tumor progession. The SEMA family is divided into eight classes mainly on the basis 
of structure and amino acid sequence. Of these eight classes, classes 3-7 comprise 
vertebrate SEMAs. The focus of this thesis will be on class 3 SEMAs (SEMA3A-G), the 
only class of secreted vertebrate SEMAs. SEMA3s are composed of several domains; an 
N-terminal SEMA domain, a plexin-semaphorin-integrin (PSI) domain, an Ig loop, and a 
C-terminal basic domain. Class 3 SEMAs also contain several furin-like endoprotease 
proteolytic cleavage sites (PCSs) that play roles in both activation and deactivation. The 
SEMA domain (~ 500 amino acids in length) forms a seven-bladed !-propeller which 
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facilitates NRP binding and may play a role in SEMA3 dimerization (Gherardi, Love, 
Esnouf, & Jones, 2004). Although other domains may play a minor role, cysteine (Cys)-
rich regions within the C-terminal basic domain play major roles in SEMA3 dimerization 
and are necessary for SEMA3 homodimerization (Klostermann, Lohrum, Adams, & 
Püschel, 1998).  
Several factors determine the bioactivity of SEMA3s. Homodimerization of 
SEMA3s are necessary for bioactivity, thus adjacent Cys723 monomer residues must form 
a disulfide bridge for SEMA3A and Cys715 for SEMA3F (Klostermann et al., 1998). 
Secondly, SEMA3 processing is also necessary for SEMA3 activation. As mentioned 
above, class 3 SEMAs have 4 major furin PCSs; PCS1 is located in the SEMA domain 
(amino acid residue 555), PCS2-4 are found in the basic domain (residues 735(2), 761(3), 
and 770(4)) (Adams, Lohrum, Klostermann, Betz, & Püschel, 1997). Adams et al. 
discovered that SEMA3A must be cleaved at residue 770 in order to be bioactive whereas 
cleavage at either of the other sites abolishes SEMA3A’s bioactivity (Adams et al., 
1997). In the majority of cases, the end result of SEMA3 processing yields either a 95-
kDa bioactive homodimer or a 65-kDa presumably biologically inactive SEMA3 
monomer (Figure 9) (Adams et al., 1997). 
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Figure 9 | Structural representation of SEMA3 family of proteins with furin-like 
protease cleavage sites. Although active SEMA3 proteins usually form dimers, the 
above structure depicts the monomer form for simplicity. The N-terminal Sema domain 
(Sema), the Ig loop domain (Ig), and the c-terminal basic domain (C) are represented 
above. Also included are the two major furin cleave sites; PCS1 and PCS3.  
 
 
The active SEMA3A competitively inhibits VEGFA, binding to the same 
extracellular region of NRP1 (Miao et al., 1999). Likewise, SEMA3F competitively 
inhibits VEGFA, binding the same extracellular domains on NRP2 (Geretti, Shimizu, 
Kurschat, & Klagsbrun, 2007). Although SEMA3s bind the CUB (a1/a2) NRP domains, a 
small part of the SEMA3 molecule interacts with the b1/b2 domain, the main site of 
VEGF165 binding (Kooi et al., 2007). By preventing NRP from binding VEGF and 
forming a bridged complex with VEGFR, SEMA3 may attenuate VEGFR’s 
autophosphorylation and thus signaling strength. SEMA3 may induce anti-angiogenesis 
and anti-lymphangiogenesis through an alternate signal transduction pathway. Most class 
3 SEMAs bind NRP2 (SEMA3B, SEMA3C, SEMA3F, and SEMA3G) with the 
exception of SEMA3A, which requires NRP1 for signal induction and SEMA3E which 
binds neither NRP (Takahashi & Strittmatter, 2001, p. 1). 
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Plexins 
Plexins (Plxns) are a family of nine transmembrane co-receptors that are 
responsible for the majority of SEMA induced signaling. Initially noted for their 
important role in cell adhesion, however, emerging roles indicate Plxn involvement in 
anti-tumorigenic and anti-metastatic processes (Bielenberg, Shimizu, & Klagsbrun, 2008; 
Ohta et al., 1995). Subdivisions exist within the Plxn family (Plxns A-D), but only A 
Plxns are involved in class 3 SEMA signaling. Although some classes of SEMA bind 
directly to Plxns, class 3 SEMAs rely upon NRP/Plxn association for signal transduction 
with the exception of SEMA3E, which binds Plexin D1 directly. The A class of Plxns 
have an extracellular, transmembrane, and intracellular regions. The extracellular region 
is composed of a SEMA domain (homologous to that of class 3 SEMAs) and alternating 
PSI and immunoglobulin-plexin-transcription (IPT) domains, which function in receptor 
activation (Hota & Buck, 2012). The intracellular domain of Plxns contain a GTPase-
activating (GAP) cytoplasmic domain which induces several GTPases; RHOD, RND1, 
RAC1, and R-Ras (Oinuma, Ishikawa, Katoh, & Negishi, 2004; Rohm, Rahim, Kleiber, 
Hovatta, & Püschel, 2000; Tong et al., 2007). 
Plxn structure is somewhat complex. Takahashi and colleagues have determined 
that the SEMA domain of class A Plxns self associates and in doing so results in self-
inhibition when not associated with a SEMA/NRP complex (Takahashi & Strittmatter, 
2001). At the same time, Takahashi et al. were able to show that binding of NRP1 to 
PlxnA1 (via Plxn’s SEMA domain) increased NRP1’s affinity for SEMA3A and that 
upon binding of SEMA3A to NRP1 PlxnA1 underwent structural modification that 
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released the Plxn’s auto inhibitory effects, leading to signal transduction (Ellis, 2006; 
Takahashi & Strittmatter, 2001).    
The majority of literature detailing the effects of SEMA signaling concerns the 
SEMA3A/NRP1/PlxnA1 pathway and its potential regulators of tumor progression via 
manipulating angiogenesis and the tumor microenvironment (Capparuccia & Tamagnone, 
2009; Neufeld & Kessler, 2008). The SEMA3A/NRP1/PlxnA1 axis has been shown to 
repulse growth cones of axons, depolymerize f-actin fibers, inhibit integrin activation in 
EC, inhibit EC migration and capillary sprouting (Miao et al., 1999; Serini et al., 2003). 
Through these and related pathways, SEMA3A overexpression has exhibited therapeutic 
potential in breast and prostate cancer, mesothelioma, myeloma, and Leukemia 
(Bachelder et al., 2003; Catalano et al., 2003; Herman & Meadows, 2007; Kigel, 
Varshavsky, Kessler, & Neufeld, 2008; Moretti et al., 2008; Vacca et al., 2006). 
However, the increasing importance of the role lymphatic vasculature and 
lymphangiogenesis play in the process of metastasis has influenced the emergence of 
another key player in this process; SEMA3F. Though some of the signaling pathways 
through which SEMA3F influences both angiogenesis and lymphangiogenesis as well as 
tumor microenvironments are unknown, many of the major players in the pathways are 
familiar and the SEMA3A/NRP1/PlxnA1 provides a rough template as to how SEMA3F 
may regulate its targets.  
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Investigating the Anti-Metastatic Effects of SEMA3F 
SEMA3F and SEMA3A are structurally similar, yet their affinities for NRPs 
differ. As previously discussed, SEMA3A preferentially binds NRP1 and carries out its 
actions via PlxnA1 mediated signaling and by competitively inhibiting VEGFR2 induced 
effects (Klagsbrun, Takashima, & Mamluk, 2002). On the other hand, SEMA3F carries 
out PlxnA1 and PlxnA2 mediated signaling, but in tissues and cells expressing NRP2 
(Chen et al., 1997). By associating with NRP2, SEMA3F attenuates both VEGFR-2 and 
VEGFR-3 mediated signaling through competitive inhibition of VEGFA, VEGFC and 
VEGFD. SEMA3F is located in 3p21.3, a chromosome region commonly deleted in 
small cell lung cancer, suggesting that SEMA3F may be a tumor suppressor gene (Sekido 
et al., 1996).  
Aside from its role as a neuronal guidance cue, SEMA3F has been shown to 
induce contraction of EC, inhibit EC proliferation, and disrupt integrin mediated 
pathways in vitro (Kessler et al., 2004). Futamura and colleagues have shown 
endogenous levels of SEMA3F expression are regulated via p53, providing yet another 
route by which p53 may negatively regulate tumor progression (Futamura et al., 2007). 
SEMA3F has also been successful in transfected tumor cell lines in in vivo studies, 
decreasing tumor cell proliferation, tumor volume, tumor blood vessel density while 
increasing the incidence of tumor necrosis (Futamura et al., 2007; Kusy et al., 2005; 
Xiang et al., 2002). In fact, studies on highly metastatic human tumor cell lines have 
shown that low expression of SEMA3F correlates with higher metastatic potential in 
prostate carcinoma, bladder carcinoma, and melanoma (Bielenberg et al., 2004). Osada et 
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al. showed that in patients suffering from ovarian cancer, a VEGF/SEMA ratio may be 
used to diagnose carcinoma progression (Osada et al., 2006). In fact, Bielenberg and 
colleagues showed that a highly metastatic human melanoma cell line, when 
overexpressing SEMA3F, exhibited abnormal and fewer intratumoral blood vessels, were 
benign, necrotic, and encapsulated by fibroblasts (Figure 10) (Bielenberg et al., 2004).  
 
 
Figure 10 | Effects of SEMA3F on tumor angiogenesis. Frozen sections of human 
melanoma xenografts. Sections were stained using CD31 antibody (green) and a nuclear 
stain, Hoescht (blue). A) Control A375SM melanoma with vasculature present 
throughout the tumor. B) A375SM melanoma transfected with SEMA3F. Very little if 
any vasculature (arrows) is present in the tumor, which appears to be surrounded by a 
large avascular region. Adapted from Bielenberg, 2004. 
 
 
In the same melanoma model, overexpression of SEMA3F prevented metastasis to both 
the lymph nodes as well as the lung (Bielenberg et al., 2004). Encapsulation, the 
surrounding of the tumor in fibroblasts and ECM typical of benign cancers, and faulty 
integrin function inhibit tumor mobility and invasive potential (Bielenberg & Klagsbrun, 
2007; Nasarre et al., 2003, 2005). In one of the few studies examining the role of 
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endogenous SEMA3F, Wu and colleagues highlighted the importance of the 
SEMA3F/NRP2/PlxnA1/2 pathway in suppressing tumor growth and metastasis in 
colorectal carcinomas (Wu et al., 2011). Even though these results illustrate SEMA3F’s 
potential and candidacy as both a suppressor of tumor growth and metastasis, the 
mechanisms of action remain largely unknown. 
One of the effects of SEMA3F/NRP2/PlxnA1 signaling is the disassembly of 
stress fibers. Recent studies have suggested that SEMA3F orchestrates f-actin 
depolymerization through PlxnA1 activation of the Ableson (ABL2) tyrosine kinase and 
subsequent deactivation of RhoA GTPase (Figure 11) (Shimizu et al., 2008). RhoA 
GTPase regulates several major eukaryotic pathways, although the most prominent one 
may be regulation of the actin cytoskeleton and thus cell shape and motility (Etienne-
Manneville & Hall, 2002). Deactivation of Rho prevents phosphorylation and 
deactivation of Cofilin, an actin-depolymerization protein involved in chemotaxis, 
phagocytosis, and cytokinesis (Aizawa et al., 2001). Activation of cofilin resulted in the 
depolymerization of f-actin stress fibers resulting in the inhibition of cellular motility and 
drastic morphologic changes within ECs (Shimizu et al., 2008). This mechanism elicits a 
characteristic morphological change, cellular collapse, and is used to test bioactivity of 
the SEMA3F protein. Ultimately, depolymerization of f-actin lowers the ability of tumor 
cells to invade blood and lymphatic vessels and ultimately metastasize to distant tissues 
and organs.  
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Figure 11 | The SEMA3F induced Plxn/ABL2/RhoA pathway. SEMA3F induced 
PlxnA1 signaling cascade. Activation of ABL2 kinase leads to deactivation of RhoA. 
Downstream of deactivated RhoA, cofilin is activated resulting in f-actin 
depolymerization and cellular collapse. From Shimizu, 2008. 
 
 
Another mechanism by which SEMA3F may induce anti-tumorigenic effects is by 
regulating EC interactions with its microenvironment. This is achieved through 
modification of integrin function. Integrins are receptors that allow cells to interact with 
ECM, enabling plasticity in angiogenesis and normal blood vessel development (Stupack 
& Cheresh, 2002). Specifically, "v!3 integrin associates with both fibronectin (FN) and 
vitronectin (VN) in ECM during VEGF induced angiogenesis but can also trigger integrin 
mediated death in the case of undesirable vessel growth (Brooks, Clark, & Cheresh, 
1994; George, Georges-Labouesse, Patel-King, Rayburn, & Hynes, 1993; Stupack, 
Puente, Boutsaboualoy, Storgard, & Cheresh, 2001). Active "v!3 has also been indicated 
in activating MMP-2 a facilitator of ECM degradation, enabling cell migration (Brooks et 
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al., 1996). Serini and colleagues were able to demonstrate that endogenous SEMA3A and 
SEMA3F performed a necessary role in regulating graded EC migration and remodeling 
during normal angiogenesis via inhibitory autocrine signaling (Serini et al., 2003). 
Furthermore, Serini et al. showed that SEMA3F interrupted focal complexes, adhesive 
structures composed of integrins responsible for cell propulsion, rendering the cell 
immobile due to an inability to attach to and move along FN and VN fibers in ECM 
(Serini et al., 2003). Several studies have suggested this may be due to FARP2 mediated 
RND1/PlxnA1 deactivation of RRAS, a GTPase responsible for !-integrin association 
with ECM (Figure 12) (Oinuma et al., 2004; Toyofuku et al., 2005; Zhang, Vuori, Wang, 
Reed, & Ruoslahti, 1996). Both tumor cells and angiogenic ECs systematically attach and 
detach to ECM elements as they migrate through stroma. By inhibiting integrin function, 
exogenous SEMA3F prevents EC and tumor cell motility and accordingly tumor 
progression and effective angiogenesis.  
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Figure 12 | The SEMA3F induced FARP2/RND1/PlxnA1 pathway. Binding of 
SEMA3F to the NRP/PlxA1 complex releases FARP2 mediated auto inhibitory effects. 
Activated RAC1 and RND1 activate the GAP domain of PlxA1 leading to the 
recruitment and inactivation of RRAS. Inactivated RRAS results in the inactivation of 
integrin and its detachment from the ECM. Adapted from Neufeld, 2008. 
 
 
Although integrins are essential ECM binding receptors, they also function in 
several important cell-signaling pathways, regulating cell cycle entry and exit, 
intracellular Ca2+ levels, lipid synthesis, and apoptosis (Varner & Cheresh, 1996). 
Integrin adhesion and activation promotes AKT and integrin-linked kinase (ILK) 
regulated pathways, affecting several important downstream targets (Kusy et al., 2005; 
Potiron et al., 2007). It has been demonstrated that SEMA3F induces the loss of active 
"v!3 and !1 integrins and may lead to the inhibition of ILK (Bielenberg et al., 2004; 
Potiron et al., 2007). Inhibition of ILK directly correlates with a reduced level of active 
! $$!
extracellular-signal-regulated kinase (ERK)-1 and -2 (Figure 13) (Potiron et al., 2007). 
ERK’s downstream effects on cell proliferation, differentiation, survival, metabolism, 
and synthesis of VEGF may provide another mechanism by which SEMA3F may inhibit 
tumor growth and progression (Kessler et al., 2004; Lloyd, 2006). On the other hand, 
AKT is a well-documented kinase with many targets (Cassinelli et al., 2013). Potiron et 
al. demonstrated that SEMA3F inhibition of integrin adhesion and thus inhibition of AKT 
led to drastic decreases in HIF-" expression, even under severely hypoxic conditions 
(Potiron et al., 2007). As mentioned earlier, HIF-1" is a major stimulant of VEGF 
synthesis, and SEMA3F induced down regulation of HIF-1" has been correlated with 
decreased expression of VEGF (Potiron et al., 2007). Presumably, as the mechanisms 
behind these pathways become clearer, more inhibitory effects of SEMA3F will be 
discovered. 
 
 
 
Figure 13 | SEMA3F induced tumor inhibition via integrin signaling. SEMA3F 
integrin inhibition prevents downstream signaling affecting multiple targets. Down 
regulation of ILK and AKT leads to decreased expression of ERK1/2 and HIF-1". 
Responsible for stimulating VEGF synthesis, down regulation of HIF-1" results in a 
lower VEGF expression. From Potiron, 2007.  
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Lymphangiogenesis, the Next Frontier 
We have highlighted the importance of metastasis as the major cause of cancer-
related deaths and the role of angiogenesis in nurturing primary tumors while providing 
them with a possible route to foreign tissue. However, the majority of Mets arising from 
carcinomas colonize distant tissues via the lymphatic vasculature (Pepper, 2001). Several 
factors are responsible for this preference in means of metastasis.  
Although both vasculature and lymphatics are comprised of ECs, the structure of 
each differs in a few key respects. Unlike capillary vessels, lymphatic capillary vessels 
are lined by a thin layer of EC, lack a protective sheath of pericytes, lack a continuous 
basement membrane, and have large interendothelial gaps (Sauter, Foedinger, Sterniczky, 
Wolff, & Rappersberger, 1998). Even though these morphological features of lymphatic 
capillaries allow them to regulate interstitial fluid volume and provide access for immune 
cells, they also provide an escape route for invasive tumor cells (Stoitzner, Pfaller, 
Stössel, & Romani, 2002). Further facilitating tumor cell entry into the lymphatics, 
evidence suggests tumors secrete factors that induce the growth of abnormally large 
peripheral lymphatic vessels, while these vessels themselves secrete chemotactic factors 
which attract tumor cells (Shields et al., 2007; Zwaans & Bielenberg, 2007). Once 
intravasated, slow lymphatic flow and pooling of cells at lymphatic nodules provide a far 
less stressful environment than vasculature for tumor cells to survive and proliferate 
(Sleeman, 2000). Once tumor cells have invaded the lymphatics, cells may either 
colonize in lymph nodes, as previously mentioned, or enter the vascular circulation, via 
the thoracic ducts, and potentially colonize distant organs (Zwaans & Bielenberg, 2007). 
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VEGFC is a potent stimulator of lymphangiogenesis and analysis of several carcinomas 
has indicated that lymph node Mets correlated with VEGFC expression (Zwaans & 
Bielenberg, 2007). Other than the tumor itself, fibroblasts, macrophages, platelets, and 
keratinocytes in the tumor environment contribute to pathological lymphangiogenesis via 
VEGFC secretion (Skobe & Detmar, 2000; Zwaans & Bielenberg, 2007). VEGFC relies 
upon both NRP2 and VEGFR3 for its pro-lymphangiogenic effect. Presumably, 
competitive inhibition of VEGFC via SEMA3F/NRP2 association along with PlxnA1/2 
coupled signaling provides a strong mechanistic basis for the use of SEMA3F as an anti-
metastatic therapeutic.   
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SPECIFIC AIMS 
 
 
This purpose of this study was to determine the efficacy of SEMA3F as a 
potential anti-tumorigenic and anti-metastatic therapeutic. Previous studies have 
illustrated SEMA3F anti-angiogenic effects on in vivo transfected tumor cell lines. To our 
knowledge, the protein has yet to be studied when administered in vivo as exogenous 
protein. Due to the expression of VEGFR3 and NRP2 on ECs as well as lymphatic 
endothelial cells, we hypothesize that SEMA3F may exhibit anti-lymphangiogenic effects 
in conjunction with its anti-angiogenic effects as previously described. By down-
regulating both of these processes, we hypothesize that SEMA3F will inhibit tumor 
growth and metastasis. 
 Our aims are to purify SEMA3F obtained from the conditioned media of 
transfected HEK293 cells. The protein will be examined for structural integrity and 
functional bioactivity via in vitro assays. Proper concentration and storage of the protein 
will also be examined in order to prevent degradation throughout purification and 
analysis. Lastly, we hope to purify enough protein to run in vivo experiments in mice by 
both SEMA3F injection and the use of osmotic slow release pumps. 
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METHODS AND MATERIALS 
Cell Culture 
General Cell Culture 
 Porcine aortic endothelial cells (PAE), porcine aortic endothelial cells transfected 
with NRP2 and red fluorescent protein (RFP)-(PAENRP2R), human embryonic kidney 
293 (HEK293) cells, bovine capillary endothelial (BCE) cells, African green monkey 
kidney (Cos7) cells, and human glioblastoma (U87MG) cells were rapidly thawed from 
liquid nitrogen using a 37°C water bath. Cells were then cultured in 100 mm culture 
dishes as monolayers using 10 mL of complete media (See Table for Cell Line Specific 
Media). Media was supplemented with 10% Fetal Bovine Serum (FBS) (Denville) and 
1% Glutamine Pen Strep (GPS) (Gibco). Cells were cultured in humidified incubators at 
37°C and either 5% or 10% CO2. Once confluent, cells were trypsinized using 0.05% 
Trypsin ethylenediaminetetraacetic acid (EDTA) (Gibco) and then subcultured in 10 mL 
of complete media. For further cell-line specific culture details see table 1. 
 When subculturing BCE cells, culture dishes were pre-coated in 1.5% gelatin 
(Difco) and left to incubate for 30 minutes to 2 hours before re-seeding trypsinized cells. 
3.75 g of gelatin was autoclaved at 121°C for 15 minutes. In a laminar flow hood, the 
gelatin was dissolved in 250 mL of sterilized distilled water. The gelatin solution was 
then stored at room temperature.  
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Table 1 | Cell Line Specific Culture Details. Cell lines were cultured according to the 
parameters listed below. All cells were stored via freezing in liquid nitrogen. 
 
Cell Line Media  % FBS % GPS % CO2 
BCE DMEM + 3 ng/mL bFGF 10 1 10 
Cos7 DMEM (Gibco) 10 1 5 
HEK293 DMEM 10 1 10 
PAE Hams F-12 (Corning) 10 1 5 
PAENRP2 Hams F-12 10 1 5 
PAENRP2R Hams F-12 10 1 5 
U87MG MEM (Gibco) 10 1 10 
 
 
Whole-Cell Protein Isolation 
 Cell culture dishes were placed on ice and twice washed with Phosphate Buffered 
Saline (PBS). Protein Lysis Buffer was made by dissolving a single complete ULTRA 
mini tablet protease inhibitor (Roche) in 10 mL of radio immuno precipitation assay 
(RIPA) buffer (Boston Bioproducts). 500!L of Lysis Buffer solution was then added to 
each 100 mm culture dish and cell lysates were scraped and collected using a cell scraper 
(BD Falcon). Following collection, cells were incubated on ice for 15 minutes. Cells were 
then centrifuged at 14,000 rpm at 4°C for 10 minutes. The supernatant was obtained and 
stored at -20°C.  
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Freezing and Storing  
 Cells were trypsinized, resuspended in complete media, then centrifuged at 1000 
rpm and 4°C. Following the aspiration of media, the pellet was resuspended in 5 mL of 
freezing buffer (respective complete media, 20% FBS, and 10% dimethylsulfoxide 
(DMSO)). The solution was then aliquoted into 1 mL cryogenic vials. Vials were then 
stored overnight at -80°C in a Mr. Frosty freezing container (Thermo Scientific) insulated 
with isopropanol. The following day, the vials were transferred to liquid nitrogen for 
long-term storage.  
 
Viral Transduction 
HEK293T or COS7 cells were cultured until approximately 70% confluence in 
100 mm culture dishes before splitting and transferring to 6-well plates. Cells in the 6-
well plate were incubated in complete media overnight (or until each well was ~70-80% 
confluent). After 24 hours various volumes of an adenoviral vector coding for SEMA3F 
(4.7 x 1010 pfu/mL) (The Harvard Gene Therapy Initiative) were added along with 
complete media and 3 !L of Polybrene (Santa Cruz Biotech), a cationic polymer used to 
increase efficiency of infection. After incubating for 24 hours, media was aspirated and 
replaced with serum free CD293 (Invitrogen). Following 24 hours of incubation, the 
serum free media was collected in low-binding micro centrifuge tubes (PGC Scientifics). 
Collected media was then run through western blot analysis to determine efficacy of 
transduction.  
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Protein Analysis  
Protein Assay 
 Concentrations of purified SEMA3F, cell lysates, and protein extraction samples 
were quantified using a Bio-Rad DC Protein Assay. Sample concentrations were 
determined via comparison to serial dilutions of bovine serum albumin (BSA) (Sigma) 
and read using a spectrophotometer plate reader. Samples and serial dilutions were mixed 
in a 96-well plate (Corning). A 2% solution was made by mixing 20 !L of Protein Assay 
Solution S (Bio-Rad) in Protein Assay Solution A (Bio-Rad). 25 !L of this A+S solution 
was added to each serial dilution and sample well followed by the addition of 200 !L of 
Protein Assay Solution B (Bio-Rad). The 96-well plate was allowed to incubate for 
approximately 5 minutes before a reading was taken by a VERSAmax microplate reader 
(Molecular Devices) at 750 nm. BSA serial dilutions were graphed and used to produce a 
curve using Excel. The best-fit line formula, generated based upon the serial dilution 
curve, was then used to calculate individual concentrations for each sample.   
 
Prepping 7.5% SDS-Page Gel for Western Blot Analysis 
 The Gel is comprised of two layers; a stacking layer of gel which lies on top of a 
resolving layer. The resolving layer solution was made by mixing 3.75 mL of 30% 
acrylamide/0.8% bis-acrylamide (National Diagnostics), 3.75 mL of 4x 1.5M tris-
HCl/0.4% SDS pH 8.8(National Diagnostics), 7.5 mL of sterilized distilled water, 50 !L 
of 10% ammonium persulfate (APS), and 10 !L of tetramethylethylenediamine 
(TEMED)(J.T. Baker Inc.). The resolving layer was pipetted into a gel cast, on top of 
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which was added a thin layer of butanol in order to maintain a flat top surface of 
resolving layer. The resolving layer was allowed to form for approximately 30 minutes. 
After 30 minutes the layer of butanol was discarded and a stacking layer solution 
comprised of 1.25 mL 0.5 M tris-HCL/0.4% SDS pH 6.8 (National Diagnostics), 0.65 
mL 30% acrylamide/0.8% bis-acrylamide, 3.05 mL of sterilized distilled water, 25 !L 
APS, and 5 !L TEMED, was added above the resolving layer. Next, either a 10- or 15-
well gel comb was inserted in the gel mold. The mold was allowed to sit for 30 minutes 
or until hardened. SDS-Page gels that were not used same day were covered with damp 
paper towels, wrapped in saran wrap, and stored in the dark at 4°C overnight.  
 
Western Blot 
 All samples, with the exception of purified SEMA3F aliquots, were adjusted 
based upon protein assay analysis for equal concentrations when loading. Samples, 
ladder, and controls were diluted using distilled water and (6x-reducing) SDS-Sample 
Buffer (Boston BioProducts). All loading samples were then boiled for 5 minutes, and 
spun down prior to loading. 7.5% SDS-Page gels were immersed in 1x running buffer 
(10x running buffer—250 mM tris base, 1.92 glycine, 1% SDS, pH 8.3 (Boston 
BioProducts)—diluted in distilled water). Before loading, individual wells were flushed. 
Approximately 20 !L was loaded in each well of a 15-well gel, and 40 !L in each well of 
a 10-well gel. Blank lanes were loaded using 15 !L of SDS-Sample Buffer and Precision 
Plus Dual Protein Dual Color Standards (Bio-Rad) was used as a standard protein ladder. 
Samples were allowed to migrate for 1.5-2 hours at 100V. Once resolved, proteins were 
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transferred to a nitrocellulose membrane (Bio-Rad) in a 1x transfer buffer solution (10x 
transfer buffer-250mM, 1.92M glycine, pH 8.4 (Boston BioProducts—diluted in distilled 
water and 20% methanol) for 2 hours at 300 mA. The membrane was then incubated with 
3% milk (3 g of non-fat dry milk blotting grade blocker (Bio-Rad)) in 1x Tris Buffered 
Saline (TBS) (10x—100mM tris-HCl, 1.5M NaCl, pH 7.4) for 30 minutes at room 
temperature. The membrane was then incubated in a primary antibody (Ab) solution 
overnight at 4°C. The membrane was then washed three times in TBS-T (1% Tween 20 
(Sigma), 1x TBS), 10 minutes/wash while agitating, then incubated with a horseradish 
peroxidase (HRP) conjugated secondary IgG Ab for 1 hour at room temperature. Once 
more, membranes were washed three times in TBS-T (10 minutes/wash while agitating). 
Membranes were immersed in exposing reagents, and then exposed using HyBlot CL 
autoradiography film (Denville Scientific). Depending on the expected level of 
expression, two separate exposing reagents were used. When detection of picogram 
amounts of antigen was needed, SuperSignal West Pico (Thermo Scientific) kit was used. 
When using West Pico, the secondary Ab dilution increased from the usual 1:3000 
(Ab:TBS-T) to 1:20,000. The membrane was immersed in a solution composed of a 1:1 
ratio of SuperSignal West Pico Luminol/Enhancer Solution to SuperSignal West Pico 
Stable Peroxide, and left to incubate for 5 minutes before exposing. Otherwise, a Western 
Lighting Plus-ECL kit was used (Perkin Elmer). The membrane was immersed in a 
solution consisting of a 1:1 ratio of Oxidizing Reagent to Enhanced Luminol Reagent for 
5 minutes before exposing. (See table for information regarding antibodies). 
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Table 2 | Antibodies and Dilutions Used During Western Blot Analysis. Western blot 
analysis was carried out using the primary and secondary antibodies detailed below. 
Secondary antibody dilutions depended upon the exposing reagent used (ECL vs. Pico). 
 
Antigen Host Animal Clonality Company Dilution (in TBS-
T) 
Band 
Location 
(kDa) 
c-myc mouse monoclonal Santa Cruz 1/1000 95, 30 
Human NRP2 
(C-9) 
mouse monoclonal Santa Cruz 1/1000 130 
Human Prox-1 rabbit polyclonal RELIATech 1/1000 82 
Human 
SEMA3F 
rabbit polyclonal Homemade  1/1000 95, 65 
HRP-linked 
Anti-Mouse 
sheep polyclonal GE 
Healthcare 
ECL-1/3000 Pico-
1/20,000 
 
HRP-linked 
Anti-Rabbit 
donkey polyclonal GE 
Healthcare 
ECL-1/3000 Pico-
1/20,000 
 
 
 
Stripping SDS-PAGE Membranes 
 Primary and secondary Antibodies were occasionally removed from probed 
membranes. Membranes were first washed with TBS-T (5 minutes while agitating). The 
membrane was then immersed in Restore Western Blot Stripping Buffer (Thermo 
Scientific) for 5-10 minutes. Membranes were washed once more in TBS-T prior to 
blocking and re-probing as described above. 
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Sypro Ruby Staining 
 Sypro ruby staining was used to analyze the purity of SEMA3F purifications. 
Samples were diluted in distilled water and SDS-Sample Buffer, boiled for 5 minutes, 
spun down, and loaded into a 7.5% SDS-PAGE gel. The gel was run for 1.5-2 hours at 
100V and then immersed in a fixative solution (10% methanol, 7% acetic acid) and 
agitated for 30 minutes. Then the gel was immersed in 50 mL of 1x Sypro Ruby Protein 
Gel Stain (Bio-Rad). The gel was incubated with the Sypro Ruby stain at room 
temperature in an aluminum foil covered container for three hours (or overnight). 
Following the Sypro Ruby staining, the gel was again washed in fixative for 30-90 
minutes before rinsing in distilled water. Images of the gel were captured via UV 
exposure using a ChemiDoc™ XRS+ System with Image Lab™ Software (BioRad). 
 
 SEMA3F Purification 
Plasmid Construction and Transient Transfection 
 Plasmid amplification and transient transfection of SEMA3F was carried out by 
Dr. Rosalyn Adam and colleagues (Department of Urology, Boston Children’s Hospital) 
according to the protocol specified by Bielenberg et al. (Bielenberg et al., 2008). The 
plasmid construct contained the full length SEMA3F sequence with the addition of a 
Myc-(for western blot probing) and Histidine (His)-tag sequences as well as a human IgK 
signal sequence. The plasmid construct was mixed with a FuGENE transfection reagent 
and serum free DMEM and applied to HEK293T cells. Cells were incubated for 16 hours 
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before media was changed to serum free CD293 media. Conditioned media was collected 
after 48 and 96 hours. 
 
Prepping of FPLC Pump and Chelating Column for Purification 
 Approximately 300 mL of conditioned media was obtained after each collection. 
Conditioned media was adjusted to pH 7.4 using 6N NaOH and 1N HCl then aliquoted 
evenly into two low-binding polymer 500 mL polypropylene centrifuge tubes (VWR). 
The media was then centrifuged at 16,900g at 4°C for 15 minutes. Following 
centrifugation, the supernatant was decanted and filtered using a Stericup 500 mL 0.22 
!m PES hydrophilic vacuum driven filter (Millipore).  
 The Fast Protein Liquid Chromatography (FPLC) pump (GE Healthcare) and 
lines were flushed with 500 mL of autoclaved double distilled water (ddH2O). The FPLC 
pump, lines, and chelating column were kept at 4°C throughout the purification process. 
A HiTrap Chelating HP 5 mL affinity column (GE Healthcare) was prepared by first 
washing with ddH2O and then was loaded with a 0.1 M NiSO4 (Sigma) solution. The 
column was then attached to the FPLC, and the lines and column were washed with 
ddH2O at a flow rate of 5 mL/minute. The column was then detached and the FPLC lines 
were flushed with PBS. The column was then reattached and washed with 50 mL of PBS 
at 5 mL/minute. 
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SEMA3F Purification  
 The His sequence in the SEMA3F plasmid construct was included in order to 
facilitate purification via the nickel column. The filtered conditioned media was then 
aspirated through the FPLC intake lead and run through the column at 5 mL/minute. 
Once the filtered conditioned media had been aspirated entirely and the column was fully 
loaded, the column was flushed with wash buffer (20 mM Na2HPO4 (Sigma), 300 mM 
NaCl, 0.05 mM imidazole (Sigma), pH 7.4) at a rate of 5 mL/minute. The column was 
detached and the FPLC pump was washed with elution buffer (20 mM Na2HPO4, 500 
mM NaCl, 500 mM imidazole, pH 7.4) at a rate of 5 mL/minute. The Column was 
reattached, and the SEMA3F protein was eluted via washing the column with elution 
buffer. The protein was collected in 1 mL aliquots using low-binding polymer micro 
centrifuge tubes. Yellowing coloration of the aliquots (indicating protein was present) 
were observed and five aliquots with the darkest coloration were selected for desalting. 
Salt and imidazole were removed by flushing the aliquots through a PD-10 desalting 
column (GE Healthcare) under sterile conditions. The protein was collected off the 
column in ten 0.5 mL aliquots using low-binding polymer micro centrifuge tubes. Further 
aliquots of each of the ten 0.5 mL aliquots were collected and stored to minimize the 
number of times the protein would undergo freeze-thaw cycles for analysis. These 
aliquots were used to determine protein concentration (via protein assay), the presence of 
full length/active SEMA3F (via Western Blot and Sypro Ruby analysis), and bioactivity 
(via spheroid and collapse assays).  
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Column and FPLC Pump Reuse 
 Following elution, the HP chelating column was detached washed by injecting 50 
mL of a metal dissociation buffer (20 mM NaH2PO4, 500 mM NaCl, 50 mM EDTA 
(Sigma)) at a rate of 5 mL/minute using a 60 mL syringe. The column was then 
reattached to the FPLC pump and, along with the FPLC pump lines, was washed with 75 
mL of ddH2O at a rate of 5 mL/minute. The chelating column was then stored in the dark 
at 4°C. 
 The pH of all buffers used during the SEMA3F purification process was checked 
prior to each use.  
 
Lyophilization 
 Purified protein was concentrated via lyophilization using a Savant SpeedVac 
Plus SC250DDA Express Centrifugal Evaporator (Thermo Scientific). Aliquots of 
purified SEMA3F were spun at 1,500 rpm and 4°C for three hours or until dry. For long-
term storage, lyophilized protein was kept at -80°C. 
 
 In Vitro Assays 
Spheroid Sprouting Assay 
 SEMA3F has anti-proliferative effects on ECs. This characteristic was used to 
determine the bioactivity of purified SEMA3F by analyzing its ability to prevent EC 
sprouting using a three-dimensional cell culture model. Methylcellulose gel was prepared 
by dissolving 2.4 g of autoclaved (121°C, 15 minutes) methylcellulose 4000 c.p. (Sigma) 
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in basal media. The methylcellulose solution was then centrifuged at 3,500 rpm and 4°C 
for 30 minutes. PAENRP2Rs were allowed to reach ~ 70% confluence, then trypsinized 
and counted using a hemacytometer (Fisher Scientific). An 8 mL cell suspension 
comprised of 800,000 cells and complete Hams-F12 media, were transferred to a clean 50 
mL centrifuge tube. 2 mL of methylcellulose gel was added to the cell suspension and 
mixed by pipetting up and down. A multi-pipette was used to load 25 !L droplets to the 
covers of four 15 cm cell culture dishes. Ten rows of eight droplets per row were seeded 
on each lid. The lids were then inverted, replaced, and allowed to incubate for 16-20 
hours at 37°C. A glass-bottom 24-well plate (Mat Tek Corporation) was placed in an 
incubator and allowed to reach 37°C. After 16-20 hours, droplets were observed using 
light microscopy to ensure cells successfully formed spheroids. Each lid was washed 
using 50 mL of PBS and spheroids suspension was collected in a 50 mL centrifuge tube. 
The cell suspension was centrifuged at 1,500 rpm and 4°C for 7 minutes. A collagen 
matrix (250 !L 10x Media 199 (Sigma), 2.1 mL collagen type 1 (BD Biosciences)) was 
mixed in a 15 mL centrifuge tube over ice. The pH of the collagen matrix was adjusted 
using 2N NaOH before adding 50 !L of HEPES Solution (Sigma) to buffer the collagen 
matrix. 45 mL of the cell suspension supernatant was aspirated and the pellet was 
resuspended in the remaining 5 mL of PBS. 2 mL of methylcellulose gel, 200 !L of FBS, 
and the collagen matrix were then added to the spheroid suspension and well mixed. 500 
!L of the spheroid/collagen matrix solution was aliquoted to eight of the wells in the 24-
well plate and allowed to incubate at 37°C for 30 minutes. 100 !L treatments were 
prepared in basal Hams-F12. After 30 minutes, negative control (100 !L Hams-F12), 
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positive control (50 ng/mL bFGF), and two concentrations of purified SEMA3F (320 
ng/mL and 640 ng/mL) treatments were added to the wells. Plates were then incubated at 
37°C overnight and then fixed and stained the following day. 
 
Spheroid Assay Fixing and Staining 
 Spheroids were fixed with 4% paraformaldehyde (PFA) (Electron Microscopy 
Sciences) for 15 minutes. Wells were washed twice with PBS (5 minutes while agitating) 
before staining. Spheroids were permeabilized using a 0.2% solution of Triton X (Sigma) 
in PBS. Spheroid nuclei were stained using Hoescht 33342 (Invitrogen). Images were 
captured using confocal microscopy. 
  
Collapse Assay 
 One of the downstream signaling events of SEMA3F binding NRP2 and signaling 
via PlxnA1/ABL2 is actin remodeling and depolymerization of f-actin stress fibers. Stress 
fiber depolymerization results in morphological changes resembling a collapsing cell. 
This assay is based upon inducing this signaling pathway in order to test whether purified 
SEMA3F was bioactive following the purification process. PAENRP2R cells were 
cultivated until ~70% confluent then trypsinized and counted using a hemacytometer. 
Approximately 4,000 cells were seeded to each well of a 16-chamber glass bottom 
chamberslide (Lab-Tek) and left to incubate at 37°C for 16-20 hours. Following the 
incubation period, wells were either treated with purified SEMA3F (640 ng/mL) or not 
(control). Following the addition of treatments, cells were allowed to incubate for 30-45 
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minutes at 37°C before they were fixed using 4% PFA. PFA was aspirated and cells were 
washed twice with PBS before adding a permeabilizing factor (0.2% triton X in PBS). 
Cells were washed twice more with PBS then stained with Hoescht. Again cells were 
washed twice more with PBS before staining f-actin fibers with a 1:250 dilution of 
Alexaflour 488 phalloidin (Invitrogen). Cells were incubated with phalloidin overnight in 
the dark at 4°C. The following day, phalloidin was aspirated from the wells and cells 
were rinsed with PBS followed by a distilled water rinse. Wells were then removed from 
the chamberslide and a cover slip was mounted using Gel/Mount (Biomedia). Clear nail 
polish was used to seal the edges of the cover slip. Cells were imaged a Leica TCS SP2 
AOBS confocal microscope with a 63x oil objective. 
 A synopsis of the purification process, protein analysis, and in vitro bioactivity 
assays can be found on the next page (Figure 14). 
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In Vivo Experiments 
Adenoviral SEMA3F Tail Vein Injection 
 In vivo effects of SEMA3F adenovirus (4.7x1010 pfu/mL) were tested in nude 
mice. Two dilutions of SEMA3F adenovirus (1:100 and 1:10) in saline were each 
injected (tail vein) in a single nude mouse (preliminary study). After six days, the mice 
were sacrificed and both serum and organs were harvested from each mouse. Organs 
were snap frozen and stored at -80°C for future analysis. Protein extraction was 
performed on the mouse livers and underwent western blot analysis. Serum was collected 
in EDTA blood collection tubes (BD) and also analyzed by western blot analysis. 
 
Protein Extraction (Whole Organs) 
 During necropsy, organs were extracted and placed in cryotubes and snap frozen 
in liquid nitrogen. Frozen organs were pulverized using a BioPulverizer (Bio Spec 
Products), collected in low-binding polymer centrifuge tubes, and then immersed in 1 mL 
of lysis buffer with protease inhibitor (see “Lysing Cells” protocol above). Pulverized 
protein was allowed to sit in lysis buffer (over ice) for 15 minutes. Protein samples were 
processed further using a sonicator (Heat Systems-Ultrasonics Inc.) until the larger 
precipitates were dissolved into solution. Samples were vortexed and incubated on iced 
between sonications to prevent heat induced protein degradation. Samples were then 
centrifuged at 10,000 rpm and 4°C for ten minutes. Both the pellet and supernatant were 
stored at -20°C. 
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Preliminary SEMA3F Treatment of A375SM in Nude Mice (Experiments M & N) 
 Female athymic nude (nu/nu) mice (n=5) were injected subdermally with 106 
human melanoma cells (A375SM). Daily injections of either SEMA3F (1 !g/40 !L of 
PBS) or control (40 !L of PBS) proximal to the tumor location began four days following 
initial injection of A375SM cells. Mice were weighed and tumor length and diameter 
were measured with a caliper every 3-5 days. Tumor volume was calculated according to 
the following formula: Volume = (tumor width2 x tumor length) x 0.52 (as described in 
Panigrahy, 2008). 27 days following the initial injection of A375SM cells mice were 
sacrificed. Mice were photographed before tumors were resected, fixed and stained for 
immunohistochemistry (IHC) analysis.  
 A second experiment (N) (n=5) was conducted using a higher daily dose of 
SEMA3F (5 !g/40 !L of saline) with 40 !L injections of saline as the control. Mice were 
weighed and tumor length and width were measured every 2-5 days. 31 days following 
the injection of A375SM cells, mice were sacrificed and tumors were resected and 
stained with CD31 and Podoplanin (RELIATech) for IHC analysis. 
 Meetu Seth and Dr. Diane Bielenberg performed all above mentioned injection 
studies (unpublished data, 2010). 
 
Preliminary SEMA3F Alzet Pump Studies (Experiments 1 & 2)  
 Two preliminary experiments were run using slow release osmotic pumps (100 
!L volume, 0.25 !L/hr release rate) (Alzet) (implanted intraperitoneal) to treat B16F10 
mouse melanoma in NRP2+/LacZ transgenic (HET) mice (PBS n=5, SEMA3F n=4). In the 
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first experiment (Exp. #1), 106 B16F10 cells were injected subdermally. Alzet pumps 
were loaded with either SEMA3F (in PBS) or PBS alone (control) and implanted nine 
days after B16F10 injection. Every 2-5 days tumor length and width of palpated tumors 
were measured. Two weeks following implantation, mice were sacrificed and tumors 
were resected and stained for IHC analysis.  
 The second study (Exp. #2) was conducted in a similar fashion with the exception 
of implantation/injection sequence. Pumps were again loaded with either SEMA3F 
treatment or PBS (control) and implanted in HET mice (PBS n=4, SEMA3F n=5) 3 days 
prior to B16F10 injection. Tumor length and width were measured at 9 days and then two 
weeks following B16F10 injection. Mice were sacrificed two weeks following B16F10 
injections and tumors were resected and stained for with CD31 and Podoplanin for 
quantitative analysis.  
Meetu Seth and Dr. Diane Bielenberg performed all above mentioned pump 
implantation studies (unpublished data, 2010). 
 
Immunohistochemistry (Mouse CD31-Paraffin Sections) 
 Paraffin-embedded tissue sections on glass slides were placed on a slide warmer 
(58°C) (MedCon) for 20 minutes in order to dry. Sections were then de-waxed using 
xylene and rehydrated by incubating in solutions of 100%, 90%, 70%, and 50% ethanol 
before washing in PBS. A Liquid Blocker Super PAP Pen (CardinalHealth) was used to 
draw a hydrophobic circle around each paraffin section. Antigen retrieval was performed 
using Proteinase K (20 µg/mL)(Roche Diagnostics) diluted in PBS for 10-20 minutes at 
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37°C. Slides were then washed in PBS before blocking endogenous peroxidases by 
incubating with peroxide solution (3% H2O2 in MeOH) for 12 minutes at room 
temperature. Slides were washed once more and then endogenous antigens were blocked 
using tris-NaCl (TNB) blocking buffer (0.1M Tris-HCl pH 7.5, 0.15M NaCl, 0.5% (w/v) 
blocking reagent (PerkinElmer) for 30 minutes. Sections were then incubated overnight at 
4°C in a 1:100 dilution of rat anti-mouse CD31 primary antibody (BD Pharmingen) in 
TNB. The following day, slides were washed in TNT buffer (1x TBS, 0.5% Tween-20) 
before incubating in biotinylated anti-rat (mouse absorbed) secondary antibody 
(1:200)(Vector) in TNB for 1 hour at room temperature. Sections were washed in TNT 
and then incubated with a 1:100 dilution of streptavidin-horseradish peroxidase conjugate 
(SA-HRP)(PerkinElmer) in TNB. Slides were washed in TNT and then incubated in 
biotinylated tyramide (diluted 1:50 in amplification buffer) for 4 minutes. Sections were 
washed again in TNT buffer followed by incubation with a 1:100 dilution of SA-HRP in 
TNB. Sections were then washed in TNT and then water before incubating in 3,3-
diaminobenzidine (DAB) Chromogen. Hematoxylin and eosin (H&E) was used to 
counter stain the sections. After counter staining, sections were washed to remove salts 
and dried over night. Cover slips were mounted using xylene and permount (Fisher 
Scientific). Sections were imaged using light microscopy, and analyzed with IPLab 
Imaging Software (BioVisions Technologies).       
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Quantitative Analysis of CD31 Stained Tumor Sections 
 Images of each of the tumor sections in both M and N studies were captured. 
Images were taken within the borders of the tumor, excluding regions of dermis and 
connective tissue surrounding the tumor mass. The maximum number of fields per tumor 
was taken using 10X objective and then analyzed using IPLab Imaging Software. 
Endothelial cell and lumenal areas (referred to as “vessel area” in figures) as well as 
micro vessel densities (MVD) was calculated by the software’s segmentation analysis. 
Scale bars were used to calibrate the pixel to !m ratio before beginning analysis. 
Segmentation highlighted only the darkly stained positive cells (ECs) differentiating them 
from surrounding tumor cells and necrotic areas. Segmentation was adjusted to highlight 
only CD31 positive cells while minimizing highlighting background (non-CD31 positive 
cells). Before final quantification, areas within fully enclosed highlighted areas (vessel 
lumens) were filled in/highlighted. IPLab software calculated the total number of 
highlighted pixels before converting this number to square micrometers to obtain the total 
EC and lumenal areas. Continuous, enclosed areas of highlighted pixels were considered 
as single vessels and counted. The number of segments was then divided by the area of a 
10X field (~ 1.13 mm2) in order to determine the MVD of each field. 
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RESULTS 
 
Purification of conditioned media yielded full-length protein 
 To our knowledge, functional full-length SEMA3F protein is not yet produced 
commercially. Previous studies on commercially available Fc chimeric, truncated 
SEMA3F have been ineffective and the protein found to be biologically inactive. In order 
to analyze the effects of SEMA3F, our lab has come up with a protocol that utilizes a 
homemade SEMA3F plasmid construct to transiently transfect HEK293 cells. The 
conditioned media is collected from these transfected cells, purified via FPLC, desalted, 
and then analyzed for structural integrity (as previously described in Bielenberg et al., 
2008) and bioactivity. Each transfection yielded approximately 300 mL of conditioned 
media and 470 !g of pure SEMA3F protein. Western blot analysis on the conditioned 
media and the FPLC flow through indicated that full-length SEMA3F was present in the 
conditioned media and absent in the FPLC flow through indicating the chelating column 
collected most if not all of the protein (Figure 15A). The majority of eluted protein was 
typically found in 5 out of the ten-1 mL FPLC elutions. Elutions containing protein were 
visibly yellow in color when compared to those without; facilitating the process of 
choosing which 5 would be run through the desalting column. Elutions containing protein 
were run through a PD10 column with distilled water in order to remove NaCl and 
imidazole and then analyzed via western blot and protein assay (Figure 15B). PD10 
aliquots were also analyzed via sypro ruby staining for a faster determination of protein 
size (Figure 15C).     
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Figure 15 | Structural analysis of purified SEMA3F. A) Western blot exposed with 
pico. Both western blots were probed using anti-c-myc primary antibody and anti-mouse 
secondary antibody. SEMA3F is present in the conditioned media (CM) but not the flow 
through (FT) indicating that most if not all protein bound the chelating column. B) A 
typical purification curve of PD10 aliquots (1-10) representing full length SEMA3F (~95 
kDa). C) Sypro ruby analysis showing mostly full length SEMA3F protein (~95 kDa). As 
a general protein stain, sypro ruby analysis also indicates the relative purity of the 
sample. Bands representing only full length and cleaved SEMA indicate the lack of non-
SEMA protein in the purified samples. Previously purified SEMA3F, positive for 
bioactivity, was loaded as a positive control (+). 
 
 
 
PAENRP2R cells were chosen due to NRP2 and RFP expression  
 An appropriate cell line for in vitro analysis must express NRP2 and be of EC 
origin. Several wild type and transfected PAE cell lines were made available for use in in 
vitro assays. Of the PAE cell lines, several were stably transfected with NRP2 
(PAENRP2) and one had been co-transfected with a vector for red fluorescent protein 
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(RFP) (PAENRP2R). Relative NRP2 expression was determined via western blot analysis 
of PAENRP2 and PAENRP2R. Both cells lines had maintained high level of NRP2 
expression after liquid nitrogen storage (Figure 16). PAENRP2R were chosen for in vitro 
experiments due to the relative level of NRP2 expression and the added benefit of RFP 
expression.  
 
  
Figure 16 | NRP2 expression in PAENRP2R cell line. Western blot analysis using anti-
human NRP2 (C9) primary antibody and anti-mouse secondary antibody. PAENRP2 and 
PAENRP2R were compared for NRP2 (130 kDa) expression.   
 
 
 
 
Lyophilization was an effective process for concentrating purified SEMA3F aliquots 
 Purified SEMA3F was effectively concentrated by lyophilization producing full-
length bioactive protein. Previous attempts at concentrating aliquots using centrifugal 
filtration devices proved ineffective as protein presumably bound the filter during 
centrifugation. On the other hand, lyophilization yielded samples that were on average 
fifteen fold more concentrated than their respective PD10 aliquots without loss or 
degradation of the protein. Aliquots of purified SEMA3F both pre- and post-
lyophilization were compared via western blot (Figure 17).   
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Figure 17 | Comparison of pre- and post-lyophilized SEMA3F protein via western 
blot analysis. Wells were loaded with the same sample volume (5 !L). Membrane was 
probed using anti-c-myc primary antibody and anti-mouse secondary antibody. Pure 
SEMA3F was loaded as a positive control (+). Lyophilization yielded mostly full-length 
protein (95 kDa) with smaller concentrations of cleaved SEMA3F (65 kDa).  
 
 
 
Purified SEMA3F was found to be biologically active 
 Purified SEMA3F was lyophilized and stored at -80°C as a powder. Lyophilized 
SEMA3F was thawed when needed and reconstituted in a lower volume of distilled water 
in order to concentrate the protein. Reconstituted SEMA3F was aliquoted and tested for 
bioactivity via several in vitro assays. SEMA3F effectively induced the collapse of 
PAENRP2R cells when administered at a concentration of 640 ng/mL (Figure 18). 
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Figure 18 | SEMA3F induces f-actin depolymerization causing PAENRP2R cells to 
collapse. PAENRP2R cells were stained with Hoescht (blue) and Phalloidin (green) and 
imaged via fluorescent confocal microscopy (63x).  A) Cells treated with complete media 
only (negative control) exhibit clear f-actin stress fibers (arrow). B) Cells treated with 
known active SEMA3F (positive control) illustrate morphological changes associated 
with f-actin depolymerization (note: stress fibers are no longer visible). C) Cells treated 
with purified, reconstituted SEMA3F collapsed expressing similar morphological 
changes as the positive control (B). D) Higher magnifications of PAENRP2R cells from 
the control group (1) and the SEMA3F treated group (2). F-actin stress fibers (arrows) are 
apparent in the control cell but not in the cell treated with SEMA3F.   
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Purified SEMA3F inhibits PAENRP2R sprouting 
 Preliminary data from spheroid analysis indicates that application of 640 ng/mL 
and 320 ng/mL of purified SEMA3F decreases EC sprouting. Initial observations show 
that spheroids treated with positive control (spheroids incubated in basal media and 50 
ng/mL of bFGF) produced many sprouts whereas those treated with a combination of 
bFGF, basal media, and purified SEMA3F displayed few if any sprouts (Figure 19). 
Quantification of these spheroid assays is underway. Since PAENRP2R cells formed the 
spheroids, we can measure the RFP of the spheroids in order to quantify the total area and 
average length of spheroid sprouts via IPLab software.  
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Figure 19 | Purified SEMA3F inhibited sprouting in PAENRP2R spheroid assays. 
Spheroids consisting of PAENRP2R cells were cultured in a methylcellulose based gel 
and treated with two concentrations of SEMA3F. Both 640 ng/mL and 320 ng/mL 
SEMA3F treatments as well as the negative control (basal media only) were observed 
having few if any sprouts (arrows). When cultured in basal media and 50 ng/mL of bFGF 
(positive control) many sprouts were seen extending from each spheroid.   
 
 
HEK293 and Cos7 transduction with adenoviral SEMA3F proved ineffective 
 In an attempt to obtain higher yields of SEMA3F transduction of SEMA3F 
protein, adenoviral transduction was tested. Both HEK293 and COS7 transductions 
proved ineffective. HEK293 cells were transduced with the SEMA3F adenovirus in 
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initial attempts. SEMA3F could not be detected in either the conditioned media or cell 
lysates when analyzed via western blot. Polybrene toxicity test results illustrated that this 
polymer was non-toxic when administered in the levels required by the transduction 
protocol. The same transduction protocol was then carried out using COS7 cells. Again 
conditioned media and cell lysates were analyzed via western blot (Figure 20). It appears 
as though the adenovirus was not able to effectively infect either the HEK293 or COS7 
cells. Cells that were infected produced relatively low amounts of intracellular SEMA3F. 
 
 
 
 
Figure 20 | SEMA3F transduced COS7 cells show slight intracellular SEMA3F 
expression. Differing volumes (!L) of adenovirus used during transduction are 
represented by each well. Control (C) was serum free media only. Membrane was probed 
with homemade anti-SEMA3F primary antibody and anti-rabbit secondary antibody. 
SEMA3F expression was found within the cells indicating the protein was not secreted.    
 
 
Adenoviral tail vein injections were unsuccessful in infecting nude mice  
 Liver and serum samples from two mice were analyzed via western blot to 
determine relative expression and size of SEMA3F protein (Figure 21). Both liver 
samples lacked SEMA3F, full-length or cleaved. Although bands were discovered near 
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65 kDa, the approximate size of cleaved SEMA3F protein, the size of the bands 
themselves, and the lack of bands at 95 kDa warranted further analysis. The membrane 
was stripped and re-probed using only secondary antibody.  Bands were once again 
visible at 65 kDa and were determined to be non-specific protein.   
 
 
 
Figure 21 | Western blot analysis determined adenoviral transduction to be 
unsuccessful in vivo. The membrane was probed with anti-SEMA3F primary antibody 
followed by anti-rabbit secondary antibody. Liver samples from both the mouse injected 
with a 1:10 adenoviral dilution (high liver-HL) and the mouse injected with a 1:100 
dilution (low liver-LL) was devoid of SEMA3F expression. Serum samples from mice 
injected with both low and high viral concentrations (low serum-LS, high serum-HS) 
were determined to express only non-specific bands. 
  
 
Daily injections of SEMA3F cause an increase occurrence of necrosis of A375SM 
tumors in nude mice 
 Although tumor volumes of mice in experiment M were relatively similar 
throughout four weeks of treatment (Figure 22B, 22C), SEMA3F injections appeared to 
induce tumor necrosis with visible scabs (Figure 22A). Initial histological analysis 
indicates that SEMA3F treated tumors had fewer intratumoral and peritumoral vessels 
(Figure 23). Also vessels in the peritumoral region appeared to be smaller and collapsed 
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in SEMA3F treated tumors when compared to those of control tumors (Figure 23). Also 
under examination is whether or not SEMA3F treated tumors are more apoptotic than 
their control counterparts. Quantitative histological analysis using IPLab Imaging 
software indicates a significant difference in vessel area as well as MVD between control 
and SEMA3f treated mice (Figure 25A).  
 
 
 
Figure 22 | Daily injections of SEMA3F lead to tumor necrosis in nude mice. A) 
Following 27 days of treatment, tumors of mice receiving daily injections of SEMA3F (1 
!g/40!L PBS) appeared more necrotic, exhibiting scabs (arrows), than the control group 
tumors. B) Tumor volume growth curves do not indicate significant difference in control 
versus SEMA3F treated tumors in either of the treatment doses. 
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Figure 23 | Experiment M: Initial histological analysis of SEMA3F treated tumors 
indicates fewer intratumoral and peritumoral vessels. Tumor sections were stained 
with CD31 antibody, indicating vasculature (brown color). Large vessel lumens can be 
seen in control tumors (arrows) as well as relatively large number of positively stained 
vessels both intratumorally and peritumorally, proximal to the dermis (D).  
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Figure 24 | Experiment N: Histological analysis of SEMA3F treated tumors does not 
indicate a significant difference in MVD or total vessel area. Tumor sections were 
stained with CD31 antibody, indicating vasculature (brown color). Large vessel lumens 
can be seen in control tumors (arrows) as well as relatively large number of positively 
stained vessels both intratumorally and peritumorally. 
! '*!
 
 
Figure 25 | Quantitative analysis from Experiments M and N indicates low dose 
SEMA3F treatment was effective. A) Experiment M analysis of A375SM human 
melanoma sections stained for CD31 determined a significant difference between average 
vessel areas of tumors treated with SEMA3F and PBS (control) (n=5), *, p < 0.005, as 
determined by Student’s t-test. Further analysis determined a significant difference 
between the MVDs of A375SM human melanoma tumors treated with SEMA3F and PBS 
treated (control) (n=5), *, p < 0.005, as determined by Student’s t-test. B) Experiment N 
analysis determined no significant difference between average vessel areas of tumors 
treated with SEMA3F and PBS (control) (n=5).  
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Preliminary analysis of tumor volumes from Experiment N indicates that increasing the 
dose of the SEMA3F treatment (5 !g/40 !L PBS) may have a slightly greater anti-
tumorigenic effect (Figure 25B). However tumor volumes between control and SEMA3F 
treated tumors were not statistically different. Histological analysis of resected tumors 
does not indicate a significant difference in the average vessel area or MVD between 
control and SEMA3F treated mice in Experiment N (Figure 25B).  
 
Initial analysis of podoplanin stained tumor sections from Experiment N 
demonstrates that SEMA3F treatment correlates with a decrease in peritumoral 
lymphatics  
 Resected A375SM tumors were stained with podoplanin, a known lymphatic 
marker. Preliminary observations indicate that SEMA3F may decrease not only the 
occurrence of peritumoral lymphatic vessels but also the size and lumenal area (Figure 
26). Ongoing quantitative analysis using IPLab software will determine whether or not 
the differences observed between SEMA3F and PBS (control) treated mice is significant.  
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Figure 26 | Resected tumors from Experiment N depict fewer and smaller lymphatic 
vessels in SEMA3F treated tumors. Tumors resected from nude mice injected with 
A375SM human melanoma stained with podoplanin and imaged at 10X. Fewer lymphatic 
vessels (pink) (arrows) can be seen in SEMA3F treated tumors than tumors treated with 
PBS (control). Most if not all of the lymphatics are located peritumorally, between the 
tumor tissue (T) and the dermis (D). 
 
 
SEMA3F pumps implanted before the initial injection of B16F10 inhibited tumor 
growth in preliminary studies 
 B16F10 tumors in HET mice reacted favorably when Alzet pumps were 
implanted before tumor cell injection (Figure 27). Histological analysis of resected 
tumors from both Experiments 1 and 2 is in progress.   
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Figure 27 | SEMA3F pumps implanted before initial injection of B16F10 in nude 
mice decreased tumor volume. A) SEMA3F pumps implanted in HET mice nine days 
following injection of B16F10 mouse melanoma cells did not significantly decrease 
tumor volume. B) Pumps implanted four days before B16F10 injection demonstrated 
significantly lower tumor volumes (n=5), *, p < 0.05, as determined by Student’s t-test. 
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DISCUSSION 
 
In the present study we have shown that pure SEMA3F can be produced via 
transient transfection and purification by FPLC. To our knowledge, biologically active 
SEMA3F is not yet available commercially. SEMA3F is a relatively large protein (~95 
kDa), the majority of which is necessary for bioactivity. Due to the complex structure and 
necessity of all domains, partial peptides of the SEMA3F protein are inactive. We have 
demonstrated that transient transfection of HIS-tagged SEMA3F and subsequent 
purification yields full length, biologically active SEMA3F protein.  
Several bioactivity assays were used to determine the functionality of purified 
SEMA3F protein. The collapse assay tests the protein’s capability to elicit a known 
downstream response—activation of Cofilin and depolymerization of f-actin stress 
fibers—resulting in observable morphological features. The spheroid assay is a means to 
measure the EC’s ability to form three-dimensional vessel-like structures in response to a 
growth factor or other stimulus. When adding a potential angiogenic inhibitor to the 
treatment we are testing the inhibitor’s ability to not only reduce EC migration but also 
the formation of complex EC architectural arrangements. This spheroid assay better 
enables us to gauge how SEMA3F may affect ECs in an in vivo environment. 
Sypro ruby analysis of purified aliquots indicates that aliquots of purified 
SEMA3F are relatively pure. Sypro ruby staining is quite sensitive. Although the darkest 
bands on the blot (95 kDa and 65 kDa) indicate full length and cleaved SEMA3F, fainter 
bands may indicate a small amount of alternatively glycosylated SEMA3F protein, 
SEMA3F doublets, or possibly a small amount of nickel binding protein that also bound 
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the chelating column. Mass spectrometry is the most accurate means by which to 
determine the purity of the SEMA3F aliquots and will be a necessary step in determining 
the success of purifying SEMA3F for clinical use.  
We have also shown that purified aliquots of protein may be concentrated by 
lyophilization without significant protein degradation or loss of bioactivity during the 
process (Figure 17).  Lyophilization of purified SEMA3F protein is important for a 
couple of reasons. We suspect lyophilized protein may be a better alternative to dissolved 
protein when freezing and may help prevent protein degradation during future freeze 
thaw cycles. Due to the relatively low yields of protein obtained from each purification 
process, combining and concentrating aliquots via lyophilization is needed to obtain 
enough protein for in vivo studies. A limited volume can be loaded into Alzet pumps and 
syringes thus SEMA3F must be concentrated to obtain levels appropriate for animal 
studies.   
 We hypothesize that adenoviral transduction may provide a viable alternative to 
transient transfection. Several factors may explain why viral studies failed to effectively 
produce SEMA3F. The viral stock used for both the transduction of HEK293, COS7, and 
tail vein injections was produced at a titer of 4.7 x 1010 pfu/mL. However, the viral stock 
had been stored at -20°C, instead of the recommended -80°C, for several years. 
Presumably, by the time the viral stock was thawed to use in these experiments the titer 
was so low as to be ineffective even when administered in relatively large volumes 
(Figure 20). These factors must be considered when determining the feasibility of future 
adenoviral studies. Viral therapy appears to be a rapidly emerging field with several 
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promising clinical studies underway (Vorburger & Hunt, 2002). Results from this study 
should not detract from future studies examining the potential of a SEMA3F recombinant 
adenovirus as an anti-metastatic therapeutic. One factor to keep in mind for future in vivo 
studies is the role of endogenous proteases on viral production of full-length SEMA3F. 
Although we know the half-life of SEMA3F in plasma is on the scale of hours and not 
minutes like VEGF, it may prove vital to combine recombinant adenovirus therapies with 
protease inhibitors to prevent cleavage and inactivation of full-length SEMA3F in animal 
models (Klagsbrun, personal communication). We are also currently testing an 
uncleavable SEMA3F protein whose PCS1 site has been mutated. 
 The first evidence of SEMA3F’s anti-lymphangiogenic potential was observed 
when treating inflammation-induced lymphangiogenesis with SEMA3F using a corneal 
suture model (Bielenberg, unpublished 2013). Interestingly, in this study SEMA3F 
treatment was only able to ward off growing lymphatic vessels and not vasculature. It 
was later discovered that capillaries in the eye do not express NRP2 and thus SEMA3F 
was unable to elicit a response. These results emphasize the complex nature of lymphatic 
vessels and vasculature, where the location of vessel may determine the expression levels 
of certain receptors. In other words, an antiangiogenic response induced by SEMA3F on 
vasculature in the cornea and vasculature in the liver or skin may differ drastically. This 
corneal suture study was also used in order to determine the appropriate doses for our 
preliminary mouse injections (Experiments M and N). 
 Experiments M and N have demonstrated the potential therapeutic anti-metastatic 
and anti-tumorigenic value of SEMA3F. To the best of our knowledge this is the first 
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time exogenous SEMA3F has been used to treat tumors in vivo. Although the effects of 
SEMA3F transfected cell lines in vivo have been studied (Figure 10) none have treated in 
vivo tumors using purified exogenous SEMA3F. Analysis of resected tumors stained for 
CD31 illustrate SEMA3F’s influence on a tumor’s blood supply with daily proximal 
injections in Experiment M (Figure 23). Additionally, the increased incidence of tumor 
necrosis/apoptosis (Figure 22A) may result from decreased perfusion within the tumor as 
a result of SEMA3F induced tumor vessel instability and overall anti-angiogenic effects. 
As the tumors enlarge, pressure within the tumor increases, forcing many intratumoral 
vessels to collapse (Padera et al., 2004). Presumably, closed lumens within the tumor 
along with a decrease in peritumoral microvessel density may lead to severe hypoxic 
conditions within the tumor resulting in necrosis and apoptosis. Interestingly, in 
Experiment M necrotic areas within PBS treated tumors were usually proximal to large 
open lumen vessels that may have arisen as a result of up-regulation of hypoxia-induced 
growth factors. However, similar results in SEMA3F treated A375SM tumors were not 
apparent as large vessels and open lumens were rare throughout the tumor sections 
(Figure 23).   
 Although volume measurements indicate daily SEMA3F injections do not 
significantly inhibit tumor growth, the lack of peripheral lymphatics (Figure 26) and 
vasculature may indicate SEMA3F’s anti-metastatic potential. Lymphatic vessels and 
vasculature provide invasive tumor cells with a conduit to metastasize to distant organs. 
Decreasing the number of intratumoral and peripheral lymphatics along with vessel 
stability (vessels with collapsed lumen) reduces the likelihood of invasive cells 
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intravasating local vessels. In fact, in a retrospective study of patients with lung 
adenocarcinoma, Zhang and colleagues have demonstrated that higher peritumoral 
lymphatic microvessel density was associated with lymphatic metastasis and decreased 
length of patient survival (Zhang et al., 2012). Quantitative analysis of CD31 stained 
tumor sections from experiment M indicate A375SM melanoma respond to daily 
SMEA3F injections (1!g/day). The total area consisting of ECs and vessel lumens was 
significantly decreased in A375SM tumors treated with SEMA3F when compared to 
A375SM tumors treated with PBS (control) (Figure 25A). This data illustrates that the 
average size of vessels in the control group was significantly larger—wider/open 
lumens—than those present in the SEMA3F treated group which tended to be collapsed. 
There was also a significant difference between MVD in the SEMA3F and Control 
groups indicating the average number of vessel was higher in the control group compared 
with that of the SEMA3F treated mice. These SEMA3F induced effects on tumor 
vasculature, which Zhang has correlated with patient survival, indicates SEMA3F’s 
potential as a possible anti-metastatic/anti-tumorigenic therapeutic.  
 Although SEMA3F treatment of A375SM achieved relative success in 
Experiment M, quantitative analysis of Experiment N demonstrated that a higher dose (5 
!g/day) of SEMA3F might be less effective in treating A375SM in nude mice. Analysis 
of CD31 stained tumor resections revealed there was no significant difference between 
average vessel and lumenal area or MVD in SEMA3F treated versus PBS (control) 
treated A375SM tumors. This may indicate that SEMA3F may be more effective at lower 
doses. However, with only five mice in each experimental group, repetition of these 
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results are warranted before therapeutic observations of exogenous SEMA3F treatment 
on tumors in vivo can be considered conclusive. Lymph nodes were collected from mice 
from both Experiments M and N and will eventually be analyzed for the presence of Mets 
to determine whether or not SEMA3F treatment decreased the frequency of Mets to 
sentinel lymph nodes. 
 It is important to mention the confounding factors that may exist in the process of 
injecting mice with A375SM, treating mice, resecting tumors, and analyzing stained 
tumor sections. The SEMA3F used in Experiment M was from a different batch than that 
used in Experiment N. SEMA3F used in experiment N was tested via collapse assay. 
However, aliquots were thawed for syringe loading and then kept at 4°C until the aliquot 
was spent. It is possible that protein in these aliquots was undergoing constant 
degradation and thus much less effective when compared to freshly thawed protein. 
When injecting A375SM human melanoma cells in nude mice the cell count from 
injection to injection may have varied slightly, resulting in variability of initial tumor 
volumes. As with any in vivo study, how one individual reacts to a certain treatment may 
not be par for the group and thus may add a certain degree of error to quantitative 
analysis especially when studying small cohorts (n=5). Resected tumors were cut in half 
and mounted for IHC analysis. Although the tumor sections were relatively equal in size 
there was some variation that may have either increased or decreased the number of field 
taken per tumor section thus adding additional error to quantitative analysis. Furthermore, 
segmentation analysis using IPLab software is dependent upon the color and brightness 
of individual pixels. Although great care was taken to establish consistency when 
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determining background from vessels, segmentation analysis was nonetheless dependent 
upon how well each section was stained for CD31. Minor variations in the background of 
each tumor section may also be a contributing factor of error in these calculations. 
Although preliminary, these results do illustrate a promising result and certainly warrant 
further studies in order to corroborate these results. It is clear that before conducting 
future experiment a system of purification and storage of SEMA3F needs to be 
determined in order to ensure the integrity of the protein and maintain consistency 
throughout repeat experiments.  
 Slow release osmotic pumps would ensure the delivery of a constant dose when 
compared to the spike of protein delivered during each injection. Initial Alzet pump 
studies have indicated SEMA3F may inhibit tumor growth. Alzet pumps (100 !L) in this 
study released SEMA3F at a rate of 0.25 !L/hr and were implanted intradermally. Alzet 
pumps released SEMA3F over a period of two weeks after which their reservoirs would 
be spent. HET mice were used in this study for two reasons. First, in order to determine 
the efficacy of Alzet pumps that only contain enough protein to treat mice for two weeks, 
we needed a relatively aggressive and fast growing tumor. Current literature has 
determined B16F10 mouse melanoma cells to be both aggressive and fast growing. 
Typically, mouse melanomas in mice grow faster than human tumors in nude mice. 
Secondly, it is easier to determine via fluorescence which vessels in HET mice express 
NRP2 using the LacZ (NRP2 biomarker) knock-in.  
In the case of pump implantation nine days after the initial injection of B16F10 
cells, the SEMA3F treatment showed no significant difference in tumor volume with that 
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of the control (Figure 27). However, when pumps were installed four days prior to the 
injection of B16F10 cells, tumor volumes in SEMA3F treated HET mice were 
significantly lower than that of the control. The effectiveness of the aforementioned 
pump study will be determined based upon histological analysis of resected tumors, 
currently in progress. If CD31 stained tumor sections paint a similar picture as those 
obtained from experiment M, SEMA3F may have great potential as an 
antitumorigenic/anti-metastatic therapeutic and steps towards future studies should be 
considered.  
 It is important to note the effects of SEMA3F are wide ranging and its prospects 
within medicine are not limited to the field of oncology. Bielenberg and colleagues have 
found NRP2 expression in visceral smooth muscle in vivo, with particularly strong 
expression in hollow organs like the bladder and intestines. In this study they determined 
that SEMA3F association with NRP2 in smooth muscle leads to cytoskeletal 
rearrangement and ultimately smooth muscle relaxation by inhibiting Rho-ROCK 
signaling (Bielenberg et al., 2012). As mentioned in the introduction, a similar 
mechanism is exploited when testing SEMA3F bioactivity via collapse assay (Figure 11). 
Bielenberg et al. tested bladder smooth muscle contractility by attaching incised bladder 
tissue, from both NRP2 wild type and knock out mice, to a force transducer within an 
organ bath while applying various concentrations of our purified SEMA3F. From these 
results, Bielenberg and colleagues speculate that SEMA3F (via NRP2/PlxnA activation) 
may alleviate pathological smooth muscle contractility originating from spinal cord 
injury (Bielenberg et al., 2012). Presently, our lab is collaborating with investigators at 
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Boston’s VA Medical Center and the Urology Department at Children’s Hospital to 
determine the potential of SEMA3F to attenuate incontinence in rats with induced spinal 
cord injuries. Results may pave the road for clinical applications of SEMA3F in the field 
of spinal cord injuries.  
   In summary, we have demonstrated the feasibility of producing, purifying, and 
concentrating biologically active SEMA3F for both in vitro and in vivo studies. 
Furthermore, in vivo studies have demonstrated SEMA3F’s ability to inhibit tumor 
angiogenesis presumably resulting in necrotic tumors with fewer intra- and peritumoral 
lymphatic vessels and vasculature. We speculate this decrease in functional vessels 
proximal to tumor formation is also indicative of the anti-metastatic potential of 
therapeutic SEMA3F. Histological analyses of Experiments M and N have provided 
evidence of SEMA3F in vivo efficacy. Ongoing analysis of Experiments 1 and 2 may 
provide further evidence of SEMA3F’s effects in vivo, and paint a clearer picture of the 
protein’s potential therapeutic value. Ideally, future experiments would expand upon the 
success of preliminary pump studies by duplicating Experiment 2’s protocol in a larger 
cohort and by collecting data at shorter intervals over the same length of time. This 
evidence supports SEMA3F’s role as an inhibitor of both tumorigenesis and metastasis 
via induction of several understood as well as several novel pathways. Further research in 
the field continues to support our data which indicates the anti-tumorigenic and anti-
metastatic effects of SEMA3F as well as the emerging role of this protein as a possible 
therapeutic in an ever growing list of carcinomas (Wu et al., 2011). We are currently 
examining the efficacy of an uncleavable SEMA3F, which has been genetically altered as 
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to prevent furin-like proteases from cleaving the protein at PCS1. This uncleavable 
“super SEMA3F” should theoretically have a longer half-life in serum and consist mainly 
of biologically active p95 SEMA3F.  
The effects of SEMA3F in Experiment M have provided us with an introduction 
to the potential for this protein to become a preventative metastasis therapy, one 
administered to patients after the removal of a primary tumor.  Pan et al. have shown that 
administering anti-VEGF treatment (such as Avastin) in combination with anti-NRP1 
antibodies exhibits additive effects on vascular remodeling and tumor growth (Pan et al., 
2007). Caunt and colleagues were able to show that an anti-NRP2 antibody that blocks 
VEGFC binding inhibits tumor lymphangiogenesis, the functionality of already 
established tumor lymphatics, and decreases the occurrence of Mets in sentinel lymph 
nodes while not effecting already established normal lymphatics (Caunt et al., 2008). 
When binding NRP2, SEMA3F fulfills a similar function as that of an anti-NRP2 
antibody by blocking VEGF binding. However, in addition to attenuating VEGF 
signaling, SEMA3F induction of multiple pathways further enhances this anti-
lymphangiogenic and anti-angiogenic response. For these reasons we speculate SEMA3F 
may be even more effective as a combination therapy, perhaps with an anti-VEGF 
therapy like Avastin or even low-dose chemotherapy.  
In conclusion, we suggest that SEMA3F is an effector of the angiogenic switch 
and should be included as an endogenous angiogenic inhibitor. Furthermore, evidence of 
SEMA3F’s potential to attenuate symptoms of spinal cord injury illustrates an emerging 
clinical role and overall therapeutic diversity of this protein. 
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